 
 
A Phase II, Open Label 
Prospective Single Center Drug 
Study Evaluating the Safety and 
Efficacy of (+)- Epicatechin in 
Subjects with Friedreich’s Ataxi 
 
NCT# [STUDY_ID_REMOVED] 
 
1/27/2017 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 1 of 49                                  CONFIDENTIAL  
  
A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+) -Epicatechin in Subjects with Friedreich’s Ataxia  
 
 
  
Regulatory Sponsor:  Ralitza H  Gavrilova, MD  
Mayo Clinic  
Medical Genetics  
200 First Street SW  
Rochester, MN  55905 
 
Study Product:  (+) Epicatechin capsules  
Protocol Number:   15-006845 
 
IND Number:   
128799  
  
  
Version 
No.  Date  Major Changes  
1 18Nov15  Initial  
2 25Mar 16 IND # added ; Section 4.5 added: replacement of 
dropped/withdrawn subjects; V itals/BP added to study 
visits; Platelets and liver  enzyme panel added to lab tests; 
Protocol Schedule of Events updated  
3 18 Oct 16  Removed PaTa test  from FARS test  
4 17 Dec 16  Section 3 added Cerebral  MRI is on 3T scanner  
Add pregnancy test week 24 Only  Troponin I will be used because using both Troponin I and T is redundant Footnote i exploratory test made optional if budget allows 
Protocol SOE updated  
5 27 Jan 17  Remove glucose tolerance test from week 12  
Change FARS scale improvement to a decrease of greater than 1 in section 3.1 
Section 5.8.2 changed to reflect new information about 
keeping the drug refrigerated.  
  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 2 of 49                                  CONFIDENTIAL  
 Table of Contents  
 
STUDY SUMMARY ............................................................................................................................................ 5 
1 INTRODUCTION  ....................................................................................................................................... 7 
1.1 BACKGROUND  ........................................................................................................................................... 7 
1.2 INVESTIGATIONAL AGENT  .......................................................................................................................... 9 
1.3 PRECLINICAL DATA ................................................................................................................................... 9 
1.4 CLINICAL DATA TO DATE ......................................................................................................................... 11 
1.5 DOSE RATIONALE AND RISK/BENEFITS  ...................................................................................................... 12 
2 STUDY OBJECTIVES  .............................................................................................................................. 12 
3 STUDY DESIGN AND VIS IT DESCRIPTION  .......................................................................................... 13 
SEE ALSO THE PROTOCOL SCHEDULE OF EVENTS  IN APPENDIX II.  .......................................................... 13 
3.1 GENERAL DESIGN  .................................................................................................................................... 15 
3.2 PRIMARY STUDY ENDPOINTS  .................................................................................................................... 17 
3.3 SECONDARY STUDY ENDPOINTS  ................................................................................................................ 17 
3.4 EXPLORATORY ENDPOINTS  ....................................................................................................................... 18 
3.5 PRIMARY SAFETY ENDPOINTS  ................................................................................................................... 18 
4 SUBJECT SELECTION ENROLLMENT AND WITHDRAWAL  ............................................................ 20 
4.1 INCLUSION CRITERIA  ............................................................................................................................... 20 
4.2 EXCLUSION CRITERIA  .............................................................................................................................. 20 
4.3 SUBJECT RECRUITMENT , ENROLLMENT AND SCREENING  ............................................................................. 21 
4.4 WITHDRAWAL OF SUBJECTS ...................................................................................................................... 22 
4.4.1  When and How to Withdraw Subjects  ............................................................................................... 22 
4.4.2  Data Collection and Follow -up for Withdrawn Subjects  .................................................................... 22 
4.5 REPLACEMENT OF DISCONTINUED OR WITHDRAWN SUBJECTS  ..................................................................... 23 
5 STUDY DRUG  .......................................................................................................................................... 23 
5.1 DESCRIPTION  ........................................................................................................................................... 23 
5.2 TREATMENT REGIMEN .............................................................................................................................. 23 
5.3 PREPARATION AND ADMINISTRATION OF STUDY DRUG ............................................................................... 24 
5.4 SUBJECT COMPLIANCE MONITORING  ......................................................................................................... 24 
5.5 PRIOR AND CONCOMITANT THERAPY  ......................................................................................................... 24 
5.6 PACKAGING  ............................................................................................................................................ 24 
5.7 MASKING /BLINDING OF STUDY  ................................................................................................................. 25 
5.8 RECEIVING , STORAGE , DISPENSING AND RETURN OF STUDY MEDICATION  ..................................................... 25 
5.8.1  Receipt of Drug Supplie s ................................................................................................................. 25 
5.8.2  Storage Conditions  ......................................................................................................................... 25 
5.8.3  Dispensing of Study Drug  ................................................................................................................ 25 
5.8.4  Return or Destruction of Study Drug ................................................................................................ 25 
6 STUDY PROCEDURES  ............................................................................................................................ 26 
7 STATISTICAL PLAN  ............................................................................................................................... 26 
7.1 SAMPLE SIZE DETERMINATION  .................................................................................................................. 26 
7.2 STATISTICAL METHODS  ............................................................................................................................ 26 
7.3 SUBJECT POPULATION (S) FOR ANALYSIS  .................................................................................................... 27 
8 SAFETY AND ADVERSE E VENTS  .......................................................................................................... 27 
8.1 DEFINITIONS  ........................................................................................................................................... 27 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 3 of 49                                  CONFIDENTIAL  
 8.2 RECORDING OF ADVERSE EVENTS  ............................................................................................................. 29 
8.3 REPORTING OF SERIOUS ADVERSE EVENTS AND UNANTICIPATED PROBLEMS  ................................................. 30 
8.3.1  Sponsor -Investigator reporting: notifying the Mayo IRB  .................................................................... 30 
8.3.2 Sponsor -Investigator reporting: Notifying the FDA  ........................................................................... 30 
8.4 STOPPING RULES ..................................................................................................................................... 31 
8.5 MEDICAL MONITORING  ............................................................................................................................ 31 
9 DATA HANDLING AND RECORD KEEPING  ........................................................................................ 31 
9.1 CONFIDENTIALITY  ................................................................................................................................... 31 
9.2 SOURCE DOCUMENTS  ............................................................................................................................... 31 
9.3 DATABASE  .............................................................................................................................................. 32 
9.4 RECORDS RETENTION  ............................................................................................................................... 32 
10 STUDY MONITORING, AUDITING, AND INSPECTI NG ....................................................................... 32 
10.1 STUDY MONITORING PLAN ................................................................................................................... 32 
10.2 AUDITING AND INSPECTING  .................................................................................................................. 32 
11 ETHICAL CONSIDERATIO NS ................................................................................................................ 33 
12 STUDY FINANCES  ................................................................................................................................... 33 
12.1 FUNDING SOURCE  ................................................................................................................................ 33 
12.2 CONFLICT OF INTEREST  ........................................................................................................................ 33 
13 PUBLICATION PLAN  .............................................................................................................................. 33 
14 REFERENCES  .......................................................................................................................................... 34 
15 ATTACHMENTS  ...................................................................................................................................... 35 
15.1 ATTACHMENT I  FRIEDREICH ’S ATAXIA RATING SCALE (FARS)  .............................................................. 35 
15.2 ATTACHMENT  II  PROTOCOL SCHEDULE OF EVENTS  ............................................................................... 35 
 
   
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 4 of 49                                  CONFIDENTIAL  
  
List of Abbreviation s 
AKT    Protein kinase B 
ALT/AST    Alanine Aminotransferase/Aspartate Aminotransferase  
AMPK   AMP -activated kinase  
BNP    B- Type Natriuretic Peptide  
BOLD    Blood Oxygenation Level Dependent 
CFR    Code of Federal Regulations  
Cho   Choline 
Cr   Creatine  
CRF    Case Report Form  
CYP    Cytochrome P450  
DTI   Diffusion Tensor Imaging 
EPI   Epicatechin  
ETC    Electron Transport Chain 
FA   Friedreich’s Ataxia 
FARA    Friedreich’s Ataxia Research Alliance  
FARS    Friedreich’s Ataxia Rating Scale  
FDA    Food and Drug Administration 
Fe-S   Iron-Sulfur 
GCP    Good Clinical Practice Guidelines  
HERG   Human Ether-a- Go-go Related Gene  
IND   Investigational New Drug (application) 
LAR    Legally Authorized Representative 
LKB    Liver Kinase B1  
LV   Left Ventricular  
Mg   Milligrams  
MRI    Magnetic Resonance Imaging  
MRS    Magnetic Resonance Spectroscopy  
MtD    Mitochondrial Disease 
Myf5    Myogenic Factor 5  
MyoD     Myogenic Differentiation Antigen  
NAA    N- acetyl Aspartate  
NAMDC    North American Mitochondrial Disease Consortium 
NO   Nitric oxide  
Nrf2    nuclear factor -E2-related factor -2 
OHP    Hydroxy-pregnenolone 
PGC -1α   Peroxisome proliferator- activated receptor  gamma coactivator 1 -  
   alpha 
PI3K    Phosphoinositide 3-kinase 
PT/PTT    Prothrombin Time/Partial Prothrombin Time  
ROS    Reactive Oxygen Species  
SIRT3    Sirtuin 3  
SOD2    Supe roxide dismutase 2 
ST2    Suppressor of tumorigenicity 2 
TID    Ter in die (three times a day)  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 5 of 49                                  CONFIDENTIAL  
 Study Summary  
Title  A Phase II, Open Label Prospective Single Center Drug Study 
Evaluating the Safety and Efficacy of (+) -Epicatechin in Subjects with 
Friedrei ch’s Ataxia  
Running Title  Safety and Efficacy of (+) -Epicatechin in  Friedreich’s Ataxia 
Protocol Number 15-006845 
Phase Phase II  
Methodology This is an open label, single center, prospective phase II drug trial to 
assess the safety and efficacy of (+) -EPI in the treatment of Friedreich’s 
Ataxia. Subjects will be evaluated at outpatient clinic visit appointments 
and interested qualified subjects will be consented and offered 
participation in this trial. Once consent has been obtained, baseline values will be established and subjects will begin treatment and follow -
up over a 24 week period. Clinical and biochemical parameters will be 
assessed at baseline and at 12 and 24 weeks after initiation of treatment.  
Overall Study Duration Two years  estimated to complete enrollment 
Subject Participation Duration 24 weeks 
Single or Multi- Site  Single center  
Objectives  Primary:  
To assess the safety and clinical efficacy from neurological, cardiac and metabolic evaluations of patients before and after treatment.  
 Secondary:  
To assess (i) up -regulation of relevant mitochondrial proteins ( frataxin 
and ETC complexes I -V) and (ii) reduction of urine F2 -isoprostane, 
before and after treatment.  
 Exploratory: To assess myocardial oxygenation  by Blood Oxygenation Level 
Dependent (BOLD) sequence cardiac MRI, and myocardial perfusion index by Regadenoson- stress-perfusion cardiac MRI, before and after 
treatment as non -invasive, more sensitive endpoints for future studies. 
 
To investigate neuroimaging biomarkers of disease progression including spinal cord and cerebellar volumetry, Diffusion Tensor 
Imaging  (DTI), and Magnetic Resonance Spectroscopy  (MRS ). 
Number of Subjects 10 subjects  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 6 of 49                                  CONFIDENTIAL  
 Diagnosis and Main 
Inclusion Criteria  Study participants between the ages of ≥10 and ≤50 must have a 
confirmed diagnosis of Friedreich ’s Ataxia with disease duration ≤7 
years and at least one affected organ system (cardiac or neurological)  
Study Product, Dose, Route, Regimen   (+)-Epicatechin 25mg capsules  will be administered orally TID for 24 
weeks, with dose escalation to 50mg TID at 3 months for subjects  not 
showing improvement.  
Duration of Administration  24 weeks 
Reference therapy  No reference therapy  
Statistical Methodology With a sample size of 10 patients we should have 80% power to detect an effect size of 1  standard deviations or larger on outcome measures  
   
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 7 of 49                                  CONFIDENTIAL  
 1 Introduction 
This document is a protocol for a human research study. This study will be carried out in accordance 
with this protocol and the applicable U nited States  government regulations including Food and Drug 
Regulations 21 CFR Part 50 (Human Subject Protections), Part 54 (Financial Disclosure of Clinical Investigators), Part 56 (Institutional Review Boards ), Part 312 (IND) and Good Clinical Practice 
guideline s, as well as  the applicabl e Mayo Clinic research policies and procedures.  
1.1 Background 
Mitochondrial disease ( MtD ) includes a large number of human disorders with a collective 
prevalence of 10 -15 cases per 100,000, resulting from functional defects in the mitochondrial 
electron transport chain (ETC). ETC defects impair the production of ATP and also enhance the 
generation of reactive oxygen species (ROS), leading to the combination of energy deficit and 
oxidative damage underlying the pathogenesis of MtD. Given the vital role played by the ETC in 
mammalian cells, ETC defects may affect virtually any tissue or organ system and present with a 
wide variety of symptoms in both children and adults. Progressive multisystem involvement occurs 
in most patients with variable combinations of neurological, muscular, cardiac, metabolic and other 
deficits  [1]. The clinical complexity of MtD  is associated with equally significant genetic complexity 
owing to the fact that a large number of both mitochondrial and nuclear genes are required for the 
biogenesis and function of the ETC. Indeed, while ETC defects were originally linked to mutations 
in mitochondrial genes, over 30 nuclear genes were subsequently implicated and more are being 
identified . Mutations in nuclear genes can cause MtD via a broad spectrum of molecular 
mechanisms that may affect the integrity of the mitochondrial genome, the a ssembly of specific ETC 
complexes, and the synthesis or delivery of metal or Fe-S cofactors needed for ETC activity [ 1].  
 
Research Idea:  While many recent advancements in genetic and biochemical testing facilitate the 
diagnosis of MtD, there is no effective therapy available for this group of disorders as a whole [ 2]. In 
light of the common underlying pathogenic mechanism of energy deficit and oxidative damage, we 
hypothesize that the induction of mitochondrial biogenesis and bioenergetics along with 
simultaneous up- regulation of the cellular antioxidant defenses is a strategy capable to ameliorate 
MtD . To test this hypothesis we propose to conduct a phase II drug clinical trial to test the efficacy 
of a pharmaceutical grade synthetically -produced form of Epicatechin (EPI) in patients with 
Friedreich's Ataxia.  
 
Why EPI? (- ) EPI is a naturally occurring flavonoid that has shown to have similar health benefits 
to exercise training  [3]. Preliminary observations suggest the existence of a signaling mechanism 
that may induce mitochondrial biogenesis and lead to regeneration of skeletal muscle fibers and neurons depleted of mitochondria, induction of endogenous anti -oxidant enzymes such as superoxide 
dismutase and catalase, and stimulation of lipid oxidative metabolism and  glucose uptake thereby 
improving plasma triglycerides and glucose  (Figure 1) [[ 4] and Cardero  Therapeutics’ unpublished 
data]. The working hypothesis is that                                                             
                               
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 8 of 49                                  CONFIDENTIAL  
 
 Figure 1  
this signaling mechanism is 
physiologically activated during exercise  
and would activate transcription factors that would induce the effects described above. Therefore , EPI should ameliorate 
MtD . This working hypothesis is supported 
by (i) evidence that EPI acts as an exercise mimetic  [
3]; (ii) the positive effects on 
cardiovascular disease and type 2 diabetes associated with the consumption of EPI -
rich foods  [5, 6]; and (iii) the positive 
effects of purified EPI on mitochondrial biogenesis  [7], oxidative stress  [8], 
metabolism [ 9, 10], skeletal muscle growth 
and differentiation  [ 11] and 
neuroprotection [ 12]. 
 The active compound (- ) EPI is found in cocoa powder, green tea  and other plants  [13]. Recent 
research has indicated that its enantiomer, (+) -EPI is more potent and more efficacious in vitro and 
in vivo compared to ( -)-EPI with  respect to stimulating new mitochondrial formation .  (+) -EPI is 
also a natural product, found in the guarana  berry that serves as the source of widely consumed 
beverages in South America  [14].  Guarana is generally recognized as s afe and a  permitted food 
additive by FDA  [15]. (+)-EPI is not commercially available in current Good Manufacturing 
Practices (cGMP ) grade monomeric form, for any purpose, research or otherwise. Cardero 
Therapeutics has developed the first scalable manufacturing process that provides pharmaceutical grade (+) -EPI. This manufacturing process has  already been accept ed by the FDA in the context of a 
previously filed IND for determining the tolerability and PK profile of (+) -EPI in healthy human 
volunteers. Given the severity of FA, we propose studying the effects of the more potent enantiomer of epicatechin . In addition, EPI can be administered orally, readily crosses the blood -brain barrier, 
and is generally recognized as a safe compound  [9, 12]. 
 
Why FA? FA is a paradigm for MtD in which intronic  trinucleotide repeat expansions in the FA 
gene lead to depletion of the mitochondrial protein frataxin [ 16]. Frataxin is an essential iron 
chaperone required for Fe- S cluster assembly, and a reduction in the levels of frataxin leads to ETC 
dysfunction, energy deficit and oxidative damage via iron- catalyzed Fenton chemistr y [17]. FA 
patients develop progressive neuro- degenerative disease often associated with cardiomyopathy, 
diabetes mellitus, and muscle weakness with a median age of onset of 10 years. Thus, we believe EPI is a promising compound for the treatment of FA given its unique biological effects that appear 
likely to be able to counteract the pathophysiology of FA and thereby slow down or stop disease 
progression.  
 Therefore, the ability of Epicatechin  to reverse oxidative injury, ameliorate congestive heart failure, 
and induce mitochondrial repletion, coupled with its safety as a dietary product, argues for investigating its therapeutic qualities in patients with FA. Moreover, Cardero Therapeutics have  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 9 of 49                                  CONFIDENTIAL  
 teamed -up with our multi -disciplinary FA group of clinicians and scientists who share a long interest 
in MtD and FA at Mayo Clinic, enabling this initial pilot study and future larger studies.  
1.2 Investigational Agent 
Description: 
Cardero Therapeutics has sy nthesized pharmaceutical grade (+) Epicatechin, a more active natural 
product enantiomer of epicatechin, which is otherwise not available in a purified form. EPI is  
associated with  signaling mechanism that induces mitochondrial biogenesis via activation of  the 
transcription factor PGC -1α [9], upregulates endogenous antioxidant mechanisms (SOD2, catalase) 
controlled by the Nrf2 (nuclear factor -E2-related factor -2) pathway [ 18], promotes fatty acid 
oxidation through regulation of SIRT3 (Sirtuin 3) signaling  [9, 19] and enhances insulin s ensitivity 
through the PI3K/AKT (Phosphoinositide 3- kinase/ Protein kinase B) pathway and AMPK  [10] 
which may further improve metabolic dysfunction in FA.  Pharmacology:   
Pharmacokinetics of both isoforms of EPI  have been described in a previous IND filed by Dr. Robert 
Henry (IND 122158),  by Barnett et al,  2015, and Ottaviani et al, 2011 [ 20, 21].  Numerous 
publications indicate the polyphenol epicatechin does not undergo Phase I hepatic metabolism mediated by cytochrome P450 oxidases. In the liver, (-)- EPI undergoes modification (by uridine-5-
diphosphate glucuronosyl- transferases, sulfo -transferases, and catechon -O-m ethyltransferases), 
which results in  glucuronide, sulfate, or methyl con jugates /metabolites , accounting for more than 
85% of the absorbed epicatechin. Tmax ranges fro m 3.2-3.8 hours and T1/2 ranges from 1.8.-3.8 
hours. Virtually no unconjugated epicatechin is observed after 1 hour. Bioavailability is approximately 30%. (+)- EPI demonstrates moderately less bioavailability and less conjugation with 
glucuronide or sulfate compared to ( -)- EPI  [21, 22].  It is less effective as an inducer of NO 
synthesis in vitro and in vivo. The half-life is less than 90 minutes for both enantiomers [ 21].  In 
addition, (+)-EPI has no inhibitory effect on the five most important P450 oxidases in a hepatic microsome assay [ 23].  In vitro, ( +)-Epicatechin demonstrates, no Human Ether-a- Go-go Related 
Gene
 (HERG) activity [ 24]and no non- selective interactions with a diverse panel of receptors and 
enzymes [ 25]. 
1.3 Preclinical Data  
Effect of ( -)-EPI on mitochondrial biogenesis in skeletal  muscle  and in patients with Diabetes and 
heart failure .  Emerging rodent and human data confirm that ( -)-EPI increases mitochondrial 
biogenesis and the expression of  mitochondrial electron transport  chain complex proteins by up 
regulating AMPK, SIRT1 and PGC1-alpha [ 3, 6, 11, 20, 26-28]. Thus (-)- EPI stimulates muscle  
mitochondrial mass/volume and increases maximal mitochondrial respiratory rate . In addition,  
(-)-EPI promotes the ability of muscle to regenerate  by upregulating  muscle growth promoters 
(optimizing follistatin/myostatin ratio)  [6]. T hese changes have been documented in the skeletal 
muscle (SkM), heart, and liver and are accompanied by improvements in exercise performance  and 
congestive heart failure.   (-)-EPI ameliorates oxidative stress and improves cardiac function. In a mouse model ( -)-EPI 
treatment resulted in improved oxidative stress evidenced by recovery of key elements of redox 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 10 of 49                                  CONFIDENTIAL  
 balance ( glutathione/oxidized glutathione ratio , thioredoxin)  and enhanced endogenous anti -oxidant 
enzymes ( superoxide dismutase 2, cat alase and citrate synthase) [ 5].  Furthermore, the investigators 
found decreases in heart and skeletal muscle fibrosis, accompanied by an improvement in muscle 
function. In a rat model of non- dystrophic heart failure oral ad ministration of ( -)-EPI effectively 
suppressed abdominal aorta ligation- induced CHF  [29]. In addition, (-)- EPI demonstrated 
preservation of myocardial structure and function in a model of chronic heart failure [ 30].  
 EPI appears to act as an exercise mimetic  [31], based on its positive  effects on cardiovascular 
disease and type 2 diabetes associated with the consumption of EPI -rich foods [13]; and the positive 
effects of purified E PI on mitochondrial biogenesis and oxidative  stress [27], metabolism [13], and 
skeletal muscle growth and differentiation [ 32]. 
 
EPI is a neuroprotectant and inducer of neural regeneration. Neuronal injury as a result of  
mitochondrial dysfunction is a component of the pathophysiology of Friedreich’s ataxia. There is 
evidence for direct effects of epicatechin  in preserving neurons.  Wild -type mice pretreated orally 
with epicatechin before middle cerebral artery occlusion (MCAO) had significantly smaller brain 
infarcts and improved neurologic deficit scores (NDS) than did a vehicle -treated group  [33].  
 
In a medium throughput screen for neuroprotective compounds using primary mixed neuronal cells and a mitochondrial toxin, epicatechin was discovered to be a potent direct neuroprotectant. It 
effectively decreased intracellular oxidative stress and normalized the signaling pathway of brain-derived neurotrophic factor (BDNF) [ 12].  
 Cell viability assays with neuronal cultures further confirmed that epicatechin can directly protect neurons against oxidative insults. With particular relevance to FA, much of the neuronal benefit appeared to be due to the induction of endogenous anti -oxidant m echanisms controlled by the Nrf2 
pathway [ 18].  
 Effects of (+) -Epicatechin in Normal Mice . Studies have been performed to evaluate effects on 
exercise capacity using wild type mice treated with either water (control), ( -)-epicatechin (1 
mg/kg/day) or (+) -epicatechin  (0.1, 0.3 or 1 mg/kg/day) . Endpoints evaluated include the 
mitochondrial biogenesis transcription factors AMPK  and PGC1- α. (Figure 2) Results indicate that 
following 2 weeks of treatment, (+) -epicatechin could  enhance exercise capacity (as assessed by 
treadmill testing,  ( Figure  3) in a magnitude similar to 1 mg/kg/day of ( -)-epicatechin but at lower 
doses (equivalency noted at 0.3 mg/kg/day). Biochemical analyses (Western blots) of muscle samples from the above mice demonstrated a similar pattern of responses, whereby (+) -epicatechi n 
was as effective at lower doses or more effective at comparable doses when probing for effects on 
recognized key modulators of metabolism.   
    
Figure 2 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 11 of 49                                  CONFIDENTIAL  
  
 
Figure 3  
 
1.4 Clinical Data to Date 
Published data for the (-) Epi study results are pertinent to this study, because (+)- EPI is an 
enantiomer of (-)- EPI with similar biological effects.  
 Effect of (-)- EPI on mitochondrial biogenesis. Taub and colleagues  [6, 28]
 recently published the 
results of a study performed in heart failure  and DM2 patients in which ( -)-EPI-rich cocoa 
administration restored SkM mitochondrial cristae density and improved the overall mitochondrial function in an orchestrated manner with increased respiratory chain protein activity as well as levels 
of multiple indicators of mitochondria biogenesis.  Effect of ( -)-EPI in Becker Muscular Dystrophy.  Dr. Craig McDonald  at UC -Davis recently 
presented the results of a pilot trial in which 7 patients with Becker muscular dystrophy completed an 8 week treatment with ( -)-EPI given at 50 mg twice a day  [4]. Muscle biopsies at baseline and at 

IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 12 of 49                                  CONFIDENTIAL  
 8 weeks demonstrated statistically significant increases in biomarkers of mitochondrial biogenesis 
(mitofillin and cristae density by EM), hormone and tissue markers of muscle regeneration 
(follistatin, Myogenic Differentiation Antigen MyoD, Myogenic Factor  5 Myf5, myogenin), 
enhanced expression of exercise- sensitive muscle transcription factors and muscle contractile 
proteins ( Liver Kinase B1  LKB 1, actin and myosin), mitochondrial biogenesis transcription factors  
(AMPK,  PGC1α), and increased levels of  muscle contractile proteins [ dystrophin, dysferlin, and 
utrophin]. McDonald also observed an increase in cardiac stroke volume, indicating improved 
cardiac function. This was confirmed by the finding that within 8 weeks there was a significant decrease in  BNP levels per patient, indicating an improvement in the severity of heart failure. 
Cardero -supplied c GMP grade (+) -epicatechin has been undergoing evaluation  at U niversity of 
California -San Diego in single and multiple dose strengths and frequency, with no adverse events 
experience thus far . 
 
In addition, when given to prehypertensive adults for 4 weeks at 100 mg/day, ( -)-Epicatechin 
improved insul in resistance [ 34].  
1.5 Dose Rationale and Risk/Benefits 
For this study, (+) -EPI will be administered orally at a starting dose of 75 mg total daily dose (25 mg 
TID)   escalated to 150mg total daily dose (50 mg TID) for those subjects not showing improvement 
at 12 weeks.  (+)-EPI plasma levels will be measured before and after 3 (+/ -1), 12 (+/-1), and 24 (+/-
1) weeks of treatment to ass ess study drug dosing compliance.   
The dosage is supported by 3 factors: 
1) Human efficacy has been demonstrated with ( -) Epicatechin  at 1.0-1.5 mg/kg [ 4, 20, 34] 
given at  50 mg twice a day for up to 8 weeks. The twice a day dosing was chosen bec ause 
once a day dosing did not demonstrate efficacy, presumably because of the short half -life ( 
Barnett et al,2015) 
2) At 1 mg/kg in animals, (+) -Epicatechin is more effective in stimulating exercise endurance 
and activating muscle AMPK and PGC1alpha than (- ) –Epicatechin. (Fig ure 2 , Figure 3 ) 
3) Because epicatechin is not subject to Phase 1 hepatic metabolism, the pharm acokinetics in 
rats is similar to that of humans and the effective dosage in rodents predicts effective dosage in humans [ 4, 26].  FA patients will range between 25 -70 kg in weight. Therefore, we will be 
well within the in vivo documented range of efficacy in rodent models and within the safe administration of (+) -EPI in  previously published pharmacokinetic studies [ 21].  
2 Study Objectives   
See Section 3  for detailed descriptions of outcomes measures/endpoints.   
 Primary Objective (s): 
To assess the clinical  safety and  efficacy  of (+) -EPI in the treatment of Friedreich’s Ataxia, based on 
changes from baseline in neurological and cardiac function, following dosing with (+) - EPI . 
 Secondary Objective (s): 
To assess changes  from baseline following  treatment with (+) -EPI. 
• Metabolic status relating to diabetes  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 13 of 49                                  CONFIDENTIAL  
 • Mitochondrial function 
 
Exploratory Objective (s): 
To assess changes  from baseline following  treatment with (+) -EPI in : 
• Myocardial oxygenation and myocardial perfusion, as possible non-invasive, more sensitive 
endpoints for future studies 
• Muscle regeneration as measured by (serum) biomarkers follistatin and myostatin  
3 Study Design and Visit Description  
See also the Protocol Schedule of Events in Appendix II. 
Visit 1: Baseline - Week 0  
At the baseline visit, the study team will review participant eligibility. For participants who meet 
inclusion criteria, an informed consent discussion will take place with subject and LAR, when 
applicable. Adequate time will be provided for the subject/LAR to read the consent and have any and all questions answered prior to signing the consent form.  Study staff will complete a  review of 
medical history and concomitant medications, conduct a physical exam and including neurological assessment with a FARS s coring for enrolled subjects . A 3 month supply of (+)- EPI will be 
dispensed to the subjects/LAR  along with  a dosing/adverse event  diary  to be completed by the 
subject and/or LAR . The diary entries will be reviewed with participants during subsequent clinic 
visits.  All study tests will be conducted at Mayo Clinic, with the exception of study drug levels and follistatin/myostatin  analysis, to be conducted by a research laboratory at UC-San Diego. The  
following evaluations  will be completed:  
• Physical Examination, Vitals, Blood Pressure  
• Drug level analysis of (+) - EPI in blood 
• Follistatin/myostatin analysis in blood  
• Friedreich’s Ataxia Rating Scale  ( FARS ) Assessment  (See Attachment   I) 
• Urine analysis  
o F2-isoprostane (8-iso prostaglandin F2, an eicosanoid produced by oxidation of tissue 
phospholipids) to assess for oxidative stress 
• Blood chemistry 
o Serum BNP, calcium, cardiac troponin I, CBC, creatinine with eGFR , frataxin, 
glucose tolerance test, hemoglobin A1C, iron, mitochondrial complex I-V levels , 
potassium, PT/PTT, sodium, ST2,  triglycerides , ALT, AST, Alkaline Phospha tase 
and ceruloplasmin [ 35].  
• Neurology studies 
o Cerebellar and spinal cord MRI with volumetry, DTI, and MRS analysis 
• Echocardiogram and electrocardiogram  
• Cardiac MRI with BOLD/Perfusion analysis  
• Urine  pregnancy test  for female subjects  
• We may collect blood for off study evaluation if budget allows  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 14 of 49                                  CONFIDENTIAL  
 o Respiratory chain function, aconitase, catalase, PGC1α, SOD2 in blood 
Week 3 (+/- 1 week): Venipuncture - No onsite visit to Mayo Clinic required  
A test kit will be mailed  or provided at visit 1 by to the participant for venipuncture blood collection 
by a local physician.  The sample shipment will be pre-addressed to the laboratory at UC -San Diego . 
Test results will subsequently be provided to the PI  and maintained with study documents for:  
• Drug level analysis of (+) - EPI in blood 
• Follistatin/myostatin level in blood 
Telephone calls between bas eline and 3 month on- site visit s:  The subjects/LAR will be contacted 
by study staff approximately every 15 days to assess progress, symptoms and dosing compliance.  If 
it appears subject is experiencing adverse changes and the Investigator feels an on -site visit is 
warranted, the subject will be asked to come in for an interi m clinic visit. 
 
Visit 2: Week 12 (+/ - 1 week)  
At Visit 2, the participant will undergo a physica l exam and FARS scoring. M edical history, changes 
to concurrent medications, adverse event diary and dosing will be reviewed and additional diaries 
dispensed, as needed.  A physical examination will be conducted.  Dosing of (+) - EPI will be 
adjusted depending on the performance of the 8m timed walk completed through the FARS assessment and/or cardiac assessment via MRI.  If the participant shows improvement (as defined in 
section 3.1)  compared to  baseline in composite score, including the 8m timed walk or cardiac 
function by MRI, the medication dosage will remain the same. If the participant shows no improvement or worsening compared to baseline, the (+) - EPI dose will be increased.  Additional 
investigations include: 
• Physical Examination, Vitals, Blood Pressure  
• Drug level analysis of (+) - EPI in blood 
• FARS Assessment  
• Blood chemistry 
o Serum BNP, calcium, cardiac troponin I, CBC, ceruloplasmin, creatinine with eGFR , 
frataxin, , hemoglobin A1C, iron, mitochondrial complex I-V, potassium, PT/PTT, 
sodium, and ST2 , triglycerides , and liver panel ( ALT, AST, and Alkaline 
Phos phatase)  
• Cardiac MRI with BOLD  
• Urine  pregnancy test  
Telephone  calls between 3 month and 6 month on- site visits:  The subjects/LAR will be contacted 
by study staff approximately every 15 days to assess progress, symptoms and dosing compliance. If 
it appears subject is experiencing adverse changes and the Investigator  feels an on -site visit is 
warranted, the subject will be asked to come in for an interim clinic  visit. 
 
Visit 3: Final Evaluation- Week 24 (+/- 1 week)  
At the final visit, the participant will undergo a physical exam and neurological/cardiac assessments.  
Changes in symptoms  and any concurrent medications will be assessed and the dosing/adverse event 
diary will be reviewed  and collected/retained . Final investigations include: 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 15 of 49                                  CONFIDENTIAL  
 • Physical Examination, Vitals, Bloo d Pressure FARS Assessment  
• Urine analysis : F2-isoprostane 
• Blood sample(s) 
o Analysis of (+) - EPI drug level and  follistatin/myostatin levels  
• BNP, Calcium, cardiac troponin I, CBC, ceruloplasmin, creatinine with eGFR , frataxin, 
glucose tolerance test, hemoglobin A1C, iron, mitochondrial complex I- V, potassium, 
PT/PTT, sodium, ST2, triglycerides, and liver panel (ALT, AST, and Alkaline 
Phosphatase)Neurology studies 
o Cerebellar  MRI conducted on a non-FDA approved compact 3T MRI scanner and 
associated software and spinal cord MRI with volumetry, DTI, and Magnetic Resonance Spectroscopy (MRS) analysis  
• Echocardiogram and electrocardiogram  
• Cardiac MRI with BOLD/Perfusion analysis  
• Urine  pregnancy test for female subjects  
• We may collect blood for off study evaluation if budget allows  
o Respiratory chain function, aconitase, catalase, PGC1α, SOD2 in blood 
3.1 General Design  
This is an open label, single center, and prospective phase II drug trial to assess the safety and 
efficacy of (+) -EPI in the treatment of Friedreich’s  ataxia. Duration of the trial including recruitment 
and final assessment is estimated at  approximately 2 years: start date early 2016 to approximately 
late 2017, depending upon recruitment rate.   Subjects will be evaluated at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this trial. Once consent has been obtained, baseline values will be established and subjects will begin treatment and follow -up over a 24 week period. Clinical and biochemical parameters shown in Table 
1 will be assessed in each patient at baseline and at 3, 12 and 24 weeks after initiation of treatment.  See Protocol Schedule of Events in Attachment II . 
 Subjects will be dispensed bottles of 25mg capsules of open- label (+) E PI with instructions for oral 
TID dosing to be taken on an out patient basis.   All subjects will start at 75 mg total daily dose . 
Those subjects showing improvement at 12 weeks as defined below, will continue at the starting dose level of 75 mg total daily dose (one, 25mg cap TID) to 24 weeks. Subjects showing no improvement or worsening at 12 weeks will have their dose escalated as described below for  the 
remainder of the study, as tolerated.  
 Dose Escalation at 12 weeks:  Those subjects showing no improvement or worsening in the 8  meter 
timed walk /FARS composite score or with no improvement in  cardiac function by MRI at the 12-
week clinical assessment, as  compared to  baseline , will have the ir dose increased  at the 12 week visit 
to 150 mg total daily dose (two, 25mg caps TID) until 24 weeks, as tolerated .   
 Neurological Status Improvement Definition :  If there is no change or the timed walk is longer  at 
12 weeks than at the baseline walk time or the FARs composite score  has not changed  or has 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 16 of 49                                  CONFIDENTIAL  
 increased , as compared to baseline FARS composite score, this will be considered no 
improvement/worsening of neurological status.  Improvement is defined as a greater than 1 point 
decrease in the FARS composite score, as compared to the baseline composite score [ 36].  
 Cardiac Status Improvement Definition :  If the cardiac function is the same as baseline or worse 
at 12 weeks , this will be considered no improvement /worsening of cardiac LV structure/function.  
 
Improvement in left ventricular structure and function by MRI is defined as  any one of the 
following :  
1. If LV mass was abnormally increased at baseline, reduction in LV mass of  > 10% from 
baseline or 
2. If LV ejection fraction was reduced  at baseline, increase in LV ejection fraction of > 5% 
from baseline or 
3. If LV end -diastolic volume was abnormally increased at baseline, reduction in LV end-
diastolic volume of > 10% from baseline. 
 Neurologic Status:  If spinal cord and cerebellar volumes  (based on 3D volumetric MRI), fractional 
anisotropy (based on DTI), and metabolites (based on 3D MRS) are worse at 24 weeks compared to baseline, this will be considered no improvement /worsening of neurologic structure/function.  
Worsening in neurologic structure and function by MRI is defined as any one of the following:  
1. If spinal cord volumes were abnormally decreased at 24 weeks compared to baseline, reduction in cord volume of  > 10% from baseline or 
2. If cerebellar volumes were abnormally decreased at  24 weeks compared to baseline, 
reduction in cerebellar volume of  > 10% from baseline or 
3. If spinal cord fractional anisotropy was abnormally decreased at 24 weeks compared to  
baseline, reduction in fractional anisotropy of  > 10% from baseline or 
4. If cereb ellar metabolite ratios (NAA/Cr, Cho/Cr, NAA/Cho) change > 5% from baseline at 
24 weeks. 
 Study drug will be dispensed at the baseline visit for 12 (+2) weeks of dosing initially  and resupplied 
at the 12 week  visit for an additional 12 (+2) weeks of dosing at either the starting dose or escalated 
dose following re -assessment for changes in neurological and cardiac functions as described above.  
 
Table 1  
Neuromuscular  Cardiac  Metabolic & 
Biochemical  
FARS  
(disability, ataxia, fine motor 
skills, peripheral neuropathy, 
and gait)  MRI  
(left ventricular mass, end -diastolic and 
end-systolic volumes, ejection fraction, 
strain analysis, myocardial fibrosis)  Glucose 
tolerance test  
 
 
Brain MRI  
(spinal cord and cerebellar 
volumetry, DTI, and MRS) Blood Oxygenation Level Dependent 
(BOLD) MRI  
(myocardial oxygenation) Whole Blood  
Hemoglobin  
A1C  
Frataxin  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 17 of 49                                  CONFIDENTIAL  
 Heart  Failure 
Biomarkers 
(BNP , and others) 
triglycerides  
Magnetic Resonance 
Spectroscopy  (lactate, N -
acetylaspartate, and choline)  Regadenoson -stress -perfusion MRI  
(myocardial perfusion index) Leukocytes  
ETC Complexes  
Other relevant 
proteins 
Bioenergetics  
 M-mode, 2D, 3D, tissue Doppler  
(left ventricular mass, volumes, systolic 
and diastolic function)  Urine  
F2-isoprostane 
 Echocardiography  
(strain imaging)   
3.2 Primary Study Endpoints  
Neurological:  
• Change from baseline score using Friedreich's  Ataxia Rating Scale (FARS Assessment)  tool 
at 12 and 24 weeks. 
• Changes in spinal cord fractional anisotropy, based on axial DTI measurements prescribed at the C1, T1, and L1 levels  at 24 weeks . 
Cardiac:  
• Changes in Cardiac MRI from  baseline to 12 and 24 weeks:  
o  Left ventricular structural and functional characteristics (systolic function by 
ejection fraction and systolic strain, diastolic function, LV mass to determine 
ventricular hypertrophy and degree of heart failure, myocardial fibrosis by late gadolinium enhancement ). 
• Changes in Echocardiogram  from baseline to 24 weeks: 
o Left ventricular mass, volumes, systolic and diastolic function, and strain. 
• Changes in Electrocardiogram from baseline to  24 weeks to assess  for electrophysiological 
improvement of the myocardium. 
• Changes in biomarkers for heart failure and hypertrophy (ST2, BNP, Cardiac Troponin) 
from  baseline, at  12 weeks and 24 weeks. 
3.3 Secondary Study Endpoints  
• Changes in spinal cord and cerebellum volume by MRI from baseline to 24 weeks after 
initiation of  therapy:  
o Spinal cord and cerebellar volumes based on high-resolution 3D volumetric T1- and T2-weighted datasets.  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 18 of 49                                  CONFIDENTIAL  
 • Metabolic change from baseline at 12 weeks and 24 weeks  measured by : 
o Glucose tolerance test, fasting blood glucose and hemoglobin A1C at basel ine,         
12 (+/-), and 24 (+/- ) weeks to assess for improvement of diabetes mellitus.  
• Change in mitochondrial biomarkers from baseline to 24 weeks: 
o Assess for upregulation of relevant mitochondrial proteins ( frataxin and ETC 
complexes I -IV) and (ii) reduction of urine F2-isoprostane as a measure of oxidative 
stress. 
3.4 Exploratory Endpoints  
• Change in cardiac stress-regadenoson and Blood Oxygenation Level Dependent (BOLD) 
MRI from baseline at 12 and 24 weeks after treatment:  
o Myocardial oxygenation by BOLD sequence on 3T MRI 
o Myocardial perfusion index via cardiac stress-regadenoson MRI from baseline to 24 
weeks  
• Change in cerebellar metabolites (Cho, Cr, NAA), based on 3D MRS data obtained over the 
posterior fossa and upper cervical cord. 
• Change in follistatin and myostatin levels from baseline at 3 (+/-1), and 24 (+/- 1) weeks as a 
measure of muscle improvement.  
3.5 Primary Safety Endpoints 
Safety endpoints will include: 
• Distribute a diary to each study participant in order to date and record symptoms of adverse events along with drug intake. All participants will be asked to contact study 
coordinator or PI via phone in the case of an adverse event, which will then be documented in the source documents.  Participants will be asked to bring the diary 
along with their drug bottles to each clinic visit.  
• Comparison between treatment groups of the incidence and types of reported adverse events  including increase in migraine head aches , bruising or bleeding. 
The consumption of cocoa products containing the epicatechins has been reported to be associated with increased likelihood of migraine development [ 37]. However, the 
migraine effect has not been validated in subsequent clinical trials, and, if it exists, 
has been attributed to the presence of phenylethylamine [ 38].  
Anti-clotting like effects have been described for foods containing  members of the 
flavonoid family including epicatechin, such as cocoa, tea, and guarana. There is no report as to the effects that epicatechin per se may have on  phenomena such as 
platelet  aggregation or clotting times  [14, 38, 39].  
The modest effects on platelet aggregation of food containing polyphenols has been cited as one basis for  beneficial crdiovascular effects. To our knowledge, no adverse 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 19 of 49                                  CONFIDENTIAL  
 event involving platelet inhibition has been described in any study of  foods or their extracts of cocoa,guarana, or tea. Nonetheless, we deemed it prudent to exclude 
patients with thrombocytopenia or clotting disorders. 
• Potential risk based on the biological activities of (+) -epicatechin includes 
hypotension through presumed mechanism of nitric oxide (NO) mediated vasodilation [ 40].  Of note is the fact that so far, no blood pressure reducing effects by 
(-)-epicatechin have been reported in normotensive subjects. With cocoa based studies, blood pressure reducing effects are only reported in humans that have high blood pressure [ 41]. In the study by Ottaviani et al., the vas odilating effects of (+) -
epicatechin in humans were only 25% of those of (-)- epicatechin when given at the 
same doses (1.5 mg/kg) [ 21].  There is the possibility that patients undergoing 
pharmacologic tr eatment for high blood pressure if given epicatechin may develop 
hypotension through additive or synergistic effects.  
• Guarana effects on toxic and behavioral parameters were assessed in rats and mice 
subsequent to acute and chronic administrations. Experimental parameters included 
tests for antioxidant capacity in vitro, in vivo, toxicological screening, body weight, 
motor activity, death rate, and histopathological examination of viscera. Guarana 
demonstrated antioxidant effects even at low concentrations by inhibiting lipid peroxidation. At high doses (1-2 g/kg IP and PO) it did not induce significant 
alterations in toxicological parameters. Consumption of liquids containing guarana 
evidenced unaltered weight of the animals even after prolonged (23 months ) 
administration. The percentage mortality was equivalent in control and guarana 
groups. The absence of toxicity of guarana was also demonstrated by 
histopathological examination, with no alterations being detected in heart, lungs, stomach, small and large  intestine, liver, pancreas, kidneys, bladder and spleen [ 42].  
• A 10 day study in which rats were dosed at 100 mg/kg/day, approximately 50X our proposed dose in humans,  demonstrated that  (+)- epicatechin  at this high dose 
demonstrated no adverse effects with respect to appetite, behavior, alertness , or appearance. No abnormalities of any organs were observed at necropsy  [43]. 
•  (+)-Epicatechin. Campos et al recently evaluated  the effects of standardized Guarana 
encapsulated dried extract on fati gue, sleep quality, anxiety, depression symptoms, 
and menopause in a group of breast cancer chemotherapy patients. Patients with progressive fatigue after their first cycle of chemotherapy were randomized to receive either guarana 50 mg orally twice daily (n=32) or placebo (n=43) for 21 days. After a 
7-day washout period, patients were crossed over to the opposite experimental arm. 
All patients were evaluated on days 1, 21, and 49. Guarana significantly improved fatigue measures vs. placebo on days 21 and 49. Guarana treatment did not produce 
any Common Terminology Criteria for Adverse Events grades 2, 3, or 4 toxicities and 
did not worsen sleep quality or cause anxiety or depression [ 44].  
Overdose  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 20 of 49                                  CONFIDENTIAL  
 • Neither the effects of overdose of (+)-epicatechin nor an antidote to overdose are known.  For reference, the intraperitoneal (-)- epicatechin median lethal dose (LD
50) reported for mice 
is 1000 mg/kg as stated in the Mater ial Safety Data Sheet  provided by suppliers such as 
Sigma -Aldrich.  
Pregnancy and Lactation 
There are no known adverse effects of natural products containing epicatechin in pregnant 
women. In a developmental toxicity study in pregnant rats using a green tea extract, the no-observable-adverse-effect level (NOAEL) corresponded to 100 mg (-)- epicatechin/kg (the 
highest dose tested).  No information is available on l evels of ( -)-epicatechin in breast milk.   
Pregnancy testing will be done at baseline and repeated at the 12
th week clinic visit.  Patients 
who have a positive pregnancy test, are pregnant or breastfeeding will be excluded from the 
study.  
4 Subject Selection Enrollment and Withdrawal  
4.1 Inclusion Criteria  
 
Subjects must fulfill all of the following criteria: 
 
Inclusion criteria:  
• Confirmed diagnosis of Friedreich’s ataxia by FXN  genetic testing and/or Frataxin enzyme 
analysis  
• Between age 10 and 50 years of age, inclusive 
• Body weight of 25 kg or higher 
• Minimum of o ne affected organ (cardiac or neurological) system, as evidenced by clinical 
signs/symptoms  
• Disease duration ≤7 years , based on onset date of FA symptoms 
• Has no known contraindication to gadolinium contrast such as severe allergy or GFR <30 
ml/min/m2.  
• Has no known contraindication to non- contrast MRI evaluation such as pacemaker or 
magnetically active metal fragments.  
• Women of childbearing age must: 
o Have a negative pre gnancy human chorionic gonadotropin test prior to receiving 
study drug.  
o Agree to use contraception for the duration of the study drug dosing, plus 1 month after completion of the study.   
4.2 Exclusion Criteria  
 
Exclusion criteria:  
• Advanced cardiac failure, NYHA Class IV.  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 21 of 49                                  CONFIDENTIAL  
 • Clinically significant comorbidities that may also lead to cardiomyopathy, for example long 
standing hypertension, familial cardiomyopathy. 
• Clinically significant comorbidities that would, in the opinion of the investigators, 
compromise the interpretation of test results.  
• Pregnant , breast -feedin g or planning to become pregnant during study timeframe . 
• Patients with contraindications to regadenoson, i. e. second - or third -degree atrioventricular 
(AV) block or sinus node dysfunction. Has  receiv ed an investigational drug within thirty (30) 
days of baseline visit. 
• Thrombocytopenia (<125 x 109/L) or prolonged PT/PTT at baseline . 
• Clinically significant hypotension ( systolic BP<90)  due to heart failure or other conditions. 
4.3 Subject Recruitment , Enrollment  and Screening  
 
Subjects may  be recruited:  
• From the Principal Investigator or  Sub- Investigator ’s clinical practices ; may also be 
identified by  Study Coordinator. 
• By physician referrals within Mayo Clinic, by referrals from  non-Mayo Clinic physicians, by 
contact made via the Mayo Clinical Trials database with a link to the national ataxia 
foundation web site, or by patient  inquiries via contacts listed on the  www.clinicaltrials.gov  
registry . 
• Mayo Clinic investigators using social media (e.g. Twitter, Facebook, YouTube, etc.) as a 
recruitment method must have the research reviewed and approved by the Mayo Clinic 
Public Affairs/Center for Social Media.  
• New proje cts proposing the use of social media as a recruitment method will contain a 
statement from the PI in the IRBe application or the research project proposal that the use of social media for recruitment of research subjects has been reviewed and approved by the Mayo Clinic Public Affairs/Center for Social Media.  
• Investigators at institutions for which the Mayo Clinic IRB is the IRB of record will include 
within the IRB application documentation of review and approval by the relying organization 
for the use of social media, or documentation that such review and approval is not required by the institution . 
Enrollment  
 
Study participants with genetically  confirmed diagnosis of FA who meet inclusion criteria and do 
not meet exclusion criteria will be enrolled according to the most current IRB  approved version of 
this protocol. Adequate time will be allowed for review of consent/assent and to ask questions about 
the study prior to enrollment.  Subjects aged 13-17 will also sign an IRB approved assent.   A copy of the signed consent/assent form will be provided to the subject/L AR and the original will be 
retained in the Investigator’s study file.  A copy of the signed forms will also be scanned into the subject’s Mayo Clinic electronic medical record.  
 
Documentation of informed consent/HIPAA authorization will involve the use of the Research 
Participant Tracking (PTrax) Digital Signature Capture technology for research informed consent 
forms/HIPAA authorization forms. This is an institutionally approved process for obtaining 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 22 of 49                                  CONFIDENTIAL  
 consent/HIPAA authorization only while the subject, and/or the subject’s representative, is in the 
physical presence of the person authorized to obtain consent. The study team may print a copy of 
the signed consent form/HIPAA authorization form for the subject or their representative. The 
consent form/HIPAA authorization form will also be available to the subject via the patient portal .  
Note: If the subject or their representative prefers not to use the Digital Signature Capture 
technology, the study team will provide a paper consent form/HIPAA authorization form for signature.  
 
4.4 Withdrawal of Subjects  
4.4.1 When and How to Withdraw Subjects  
Subject Withdrawal Criteria  
• The end of the trial for a patient will be defined for this study as (1) completion of the final 
24 week evaluation, (2) deat h, (3) withdrawal of consent, (4) if the patient is lost to follow -up 
at 12 weeks clinic visit, the date of the patient’s last visit for which data is available.   
• Patients may be withdrawn from this trial  for the reasons provided below: 
Withdrawal for Adverse Event  
• A patient who experiences an adverse event during the study drug administration that the Investigator judges to be related to the study drug and poses a significant risk to the patient will have the study drug discontinued. All scheduled data will be collected and the patient 
will be included in all safety analyses.  
Withdrawal of Consent 
• Patients for whom Informed Consent is withdrawn will have study drug discontinued (if the decision occurs during the study period). No further data collection will be done without 
written consent for follow- up data collection. All available data on these patients will be 
included in the safety analyses.  
• Investigator Decision to Withdraw Patient  Should the Investigator determine that it is in the 
best interest of a patient to be withdrawn from the trial, the drug will be immediately discontinued (if the decision occurs during the study period). All scheduled data deemed 
appropriate by the Investigator will be collected and the patient will be included in all safety analyses.  
• Pregnancy ;  If a subject’s pregnancy test is positive at 12 weeks, subject will be discontinued 
from further study participation and any dispensed study medication will be retrieved from 
the subject.  Subject and child will be followed for potential adverse effects of study drug dosing. 
4.4.2 Data Collection and Follow- up for Withdrawn Subjects  
 Even though a subject has withdrawn from the study, it may be important to collect some follow-up 
or survival data on such subjects throughout the protocol defined follow- up period. Such data is 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 23 of 49                                  CONFIDENTIAL  
 important to the integrity of the final study analysis since early withdrawal could be related to the 
safety profile of the study drug.  If a subject withdraws consent to participate in the study, for subject 
safety reasons, attempts should be made to obtain permission to collect  follow up information 
whenever possible.   
4.5 Replacement of Discontinued or Withdrawn S ubjects  
Subjects who discontinue or are withdrawn prior to completing twenty -four (24 ) weeks of treat ment 
will be replaced, to achieve a target o f ten subjects completing 24  weeks of dosing with study 
medication.  The number replaced may be limited to  the available inventory of (+) Epicatechin 
capsules.  
 
5 Study Drug  
5.1 Description  
 
(+) EPI will be manufactured by Syngene Corporation in Bangalore, India for Cardero Therapeutics and provided without charge to study subjects.  The drug product will be provided to Mayo Clinic as  
25mg gelatin capsules, packaged in 42 capsules per high density polyethylene bottle .   
5.2 Treatment Regimen  
 The start ing total daily dose will be 75 mg per day (one 25mg capsule taken TID)  Dose escalation 
for some subjects, as described above, will occur at 12 weeks to 150mg total daily dose (two, 25mg capsules taken TID).  
 
Starting 
Dose  
 Dispense 
12 week  
supply + 
2 week s 
overage 
@ BL 
visit  Increase Dose 
at 3 months  
(for some subjects)  Dispense 12 week  
supply  + 2 week s 
overage at 12 
week Clinic Visit  
 Total # Bottles (& 
caps)  Dispensed to 
each Subject  
75 mg/day  
 one cap TID  
 3 caps/day  7 bottles 
of 42  
(294 caps ) 
 150 mg/day  
 two caps TID  
 6 caps per day  7 bottles of 42  
caps ( 294 caps )   
 OR escalated dose:  
14 bottles of 42 
caps ( 588 caps ) 
 14 bottles ( 588 
caps) 
-------------------------  
21 bottles (882 
caps) 
Escalated dose  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 24 of 49                                  CONFIDENTIAL  
 5.3 Preparation and Administration of Study Drug  
• The study drug will be shipped to, stored  by and dispensed from the Mayo Clinic Out- 
Patient Research Pharmacy  located in the  
 
• The study drug will be dispensed to subject/LAR, labeled to be taken  orally as described in 
section 5 .2 above. 
• Certifi cates of Analysis and clinical supply expiry date extensions  as provided by Cardero 
Therapeutics, based on  ongoing, concurrent stability studies, should be emailed to  
  
5.4 Subject Compliance Monitoring  
Stu
dy medication will be dispensed as part of the Baseline and 3 month study visits at Mayo Clinic, 
to be taken home with the subject. A dosing and adverse event diary will be provided to the subjects, 
who will be asked to record the dates/ times of medication intake  and any unusual symptoms .   The 
subjects will be asked to bring their diary and the previously dispensed  bottles (empty, partial and 
unused) to the 3 month visit for review by study staff.  Parents or guardians of participants younger than 18 years of age will be asked to supervise and/or provide the medication to their child and 
ensure the diaries  are co mpleted .   
In addition to the dosing diary, the subjects/LARs will be contacted periodically between on- site 
visits to assess doses are being taken as prescribed.  
A count of capsule s returned at the 3 month visit will be performed by a study team 
member /pharmacy, and  the number of returned capsules and compliance will be  documented. 
The blood levels of (+) -EPI will be measured subsequent to the visits to provide the most accurate 
measure of dosing compliance.  
If it is determined by study staff by  review  of diary, returned amounts and interview that the subject 
did not take 50% or greater of the daily dose for 3 days in any given week, the subject will be asked to become compliant. If it is determined by the above criteria to be non- compliant a second time , the 
subject will be dropped from the study. 
Completed dosing diaries will be retained with the site’s study source documents.  
5.5 Prior and Concomitant Therapy  
All concomitant medications will be allowed and at the time of enrollment and through study period  
will be recorded and current medications will be recorded at each clinical follow -up. 
5.6 Packaging 
25 mg capsules of open-label study medication will be packaged 42 capsules  per bottle.  The bottles 
will be subsequently labeled by the Research Pharmacy for each subject , based on a written 
prescription by a Study Investigator.   A 3 month supply will be dispensed at the Baseline visit and 
again at the 3 month visit, as specified in Section 3.1.  An overage amount ( 2 week  supply) will be 
dispensed to allow for flexibility in visit scheduling.  
 

IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 25 of 49                                  CONFIDENTIAL  
 In addition to dosing directions, the bottles shall bear a label with the statement "Caution: New 
Drug --Limited by Federal (or United States) law to investigational use." 
5.7 Masking/ Blinding of Study  
Not applicable; the study medication will be open label. 
5.8 Receiving, Storage, Dispensing and Return of Study Medication  
5.8.1 Receipt of Drug Supplies  
The Mayo Clinic Research Pharmacy will maintain drug shipment and dispensing accountability 
records, including shipping receipts/packing slips for incoming shipments of (+) EPI and dates/number of capsules/bottles and the lot numbers dispensed to subjects.  Expiry dating/retest dates will be provided by Cardero Therapeutics, based on ongoing stability testing.  Documentatio n of expiry/re- test dates will be retained with study records.  
 Subject dosing/AE diaries will be provided to the subject/LAR by the study team with completion instructions.  Subjects will be asked to bring their completed diaries back to the site, with a ny full or 
partial bottles to facilitate  reconciliation.  
 The quantity of capsules dispensed, taken, returned or discarded by the subject will be reconciled by the study team during visits to determine compliance with the prescribed dosing regimen.  
 Study drug r econciliation will be documented in study records. 
5.8.2 Storage Conditions  
Capsules will be  stored in HDPE bottles as packaged by Syngene, and maintained at 2 to 8 degree 
storage within the Mayo Clinic Research Pharmacy .  Subjects /LAR  will be advised to keep bottles 
refrigerated in their homes. 
5.8.3 Dispensing of Study Drug  
A prescription will be written, signed by an Investigator and faxed to the Research Pharmacy  for the 
baseline and 3 month visit  dispensing. The  subject/LAR will either pick up the medication at the 
Out-Patient Pharmacy or if picked up in advance by a study team member, will be  provided to the 
subject  by the study team  with a dosing/AE diary. 
5.8.4 Return or Destruction of Study Drug  
At the completion of the study, there will be a final reconciliation of drug amounts shipped, 
dispensed, return ed, and remaining.  This reconciliation will be included in study files.  Any 
discrepancies noted will be documented and investigated, prior to return or destruction of unused 
study drug.  Any investigational drug destroyed on site according to institutional waste policy will be documented by  the Research Pharmacy.  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 26 of 49                                  CONFIDENTIAL  
 6 Study Procedures   
The schedule of events for patients enroll ed in this trial is shown in Attachment II.  See Section 3 for 
visit descriptions.  
7 Statistical Plan  
Statistical analysis will be performed using SAS version 9.3 (SAS Inc., Cary, NC). All tests will be 
two sided and p-values less than 0.05 will be considere d statistically significant.  
7.1 Sample Size Determination  
A recent single -center open -label pilot study enrolled eight adults with genetically -confirmed Becker 
muscular dystrophy, who received 100 mg/day of EPI orally for 8 weeks. The data showed l inear 
decrease in plasma B -Type Natriuretic Peptide (BNP) levels, a validated biomarker of congestive 
heart failure [ 15]. Assuming a common standard deviation of 234.3 as seen in the Becker pilot study, 
with a sample size of 10 patients we should have 80% power to detect an effect size (on BNP and possibly other biomarkers) of 1at a 5% level of significance based on a paired  t-test. NQuery 
Advisor version 6.0 was used for sample size calculations. 
7.2 Statistical Methods  
Descriptive Statistics  
All numerical data will be imported into a dedicated application of highly -innovative multivariate 
pattern recognition software developed at Mayo by   
) that provides an integrated analysis of outcome measures after statistical 
adjustment for one or more relevant covariates.  Descriptive summaries will be reported as 
frequencies and percentages for categorical variables and as mean (standard deviation) or median 
(inter -quartile range) for contin uous variables of interest. 
 
Handling of Missing Data 
Data edit checks will be performed to assess outliers or any inconsistencies done at the time of data 
entry. No imputations will be performed for any missing data.  
Multiplicity  
Given the smaller sample  size, no formal adjustment for multiple comparisons will be performed . 
We will however, report both raw (unadjusted) and false discovery rate corrected p -values.  
 Primary Hypothesis:  
In light of the common underlying pathogenic mechanism of energy deficit and oxidative damage, 
we hypothesize that the induction of mitochondrial biogenesis and bioenergetics along with 
simultaneous upregulation of the cellular antioxidant defenses is a strategy capable to ameliorate 
MtD . To test this hypothesis we propose to conduct a phase II drug clinical trial to test the efficacy 
of a novel synthetically-produced form of Epicatechin (EPI) in patients with Friedreich's  Ataxia 
(FA).  For continuous endpoints such as FARS assessment, we will calculate changes from baseline 
to 12 weeks and 24 weeks. These will be summarized and mean (standard deviation) or median (inter -quartile range). We will also report 95% confidence intervals. Formal comparison to assess 

IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 27 of 49                                  CONFIDENTIAL  
 efficacy of intervention will be performed using paired t-test or Wilcoxon signed rank test as 
appropriate. Analysis will also be performed using percent changes from baseline to 12 week and 24 week to account for baseline discrepancies. Data will be displayed graphically using scatter  plots to 
show the trends over time. Categorical outcomes will be compared using McNemar’s test as a test of paired proportions to account for paired nature of the data.  
 
Secondary Hypothesis 1:   
• Upregulate mitochondrial biogenesis via activation of the transcription factor PGC- 1α [9] 
which is downregulated in FA [ 45]; this may lead to higher levels of frataxin as well as 
higher levels of Fe-S proteins critical for ATP production. 
• Upregulate endogenous antioxidant mechanisms (SOD2, catalase) controlled by the Nrf2 
pathway [ 18] which is inhibited in FA cells  [46]; this may enhance FA cells resistance to 
iron-catalyzed oxidative damage.  
• Promote fatty acid oxidation through regulation of SIRT3 signaling [ 9, 19] which is inhibited 
in FA cardiac cells and believed to contribute to the FA cardiomyopathy [ 47]. 
• Enhance insulin sensitivity through the PI3K/AKT pathway and AMPK [ 10] which may 
further improve metabolic dysfunction in FA. 
• Through the basic mechanisms described above, (+)- EPI treatment will ultimately prevent 
further loss of neuronal, cardiac, and pancreatic β cells and thereby delay or arrest FA neurodegeneration, cardiomyopathy and diabetes. 
 
Statistical analy sis approach for secondary endpoint will be similar to approach listed above for 
primary endpoints.   
Interim Analysis  
Interim analysis will be performed after 50% i.e. 5 out of 10 patients have completed 12 week 
follow- up. Sample size at interim analysis is too small to reach required p -value for stopping 
decision based on O’Brien Flemming Stopping boundary criterion (i.e. p-value less than 0.0054 for stopping at interim analysis . Thus decision of stopping versus continuation of the study will be based 
on clinical significance rather than statistical significance. We will consider treatment to be efficacious if the cardiac MRI , neurologic MRI, and /or FARS score improve by greater than 30% at 
3 months. 
7.3 Subject Population(s) for Analysis  
Protocol- compliant population:  Any subject who participated and received the protocol required 
study drug exposure. 
8 Safety and Adverse Eve nts 
8.1 Definitions  
Unanticipated Problems Involving Risk to Subjects or Others  (UPIRTSO)  
Any unanticipated problem or adverse event that meets the following three criteria:  
• Serious : Serious problems or events that results in significant harm, (which may be physical, 
psychological, financial, social, economic, or legal) or increased risk for the subject or others 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 28 of 49                                  CONFIDENTIAL  
 (including individuals who are not research subjects). These include: ( 1) death; (2) life 
threatening adverse experience; (3) hospitalization - inpatient, new, or prolonged; (4) 
disability/incapacity - persistent or significant; (5) birth defect/anomaly; (6) breach of confidentiality and (7) other problems, events, or new information (i.e. publications, DSMB reports, interim findings, product labeling change) that in the opinion of the local investigator may adversely affect the rights, safety, or welfare of the subjects or others, or substantially compromise the research data, AND  
• Unanticipated: (i.e. unexpected) problems or events are those that are not already described 
as potential risks in the protocol, consent document, not listed in the Investigator’s Brochure, or not part of an underlying disease. A problem or event is "unanticipated" when it was unforeseeable at the time of its occurrence. A problem or event is "unanticipated" when it occurs at an increased frequency or at an increased severity than expected, AND  
• Related : A problem or event is "related" if it is possibl y related to the research procedures.  
 
Adverse Event  
An untoward or undesirable experience associated with the use of a medical product (i.e. drug, 
device, biologic) in a patient or research subject.  Adverse events are classified as serious or non -
serious. 
Serious Adverse Event  
An adverse event or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes:  
• death  
• Is considered a life -threatening adverse event   
• inpatient hospitalization or prolongat ion of existing hospitalization  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions 
• a congenital anomaly/birth defect.  
 
Important medical events that may not result in death, be life -threatening, or require hospitalization 
may be considered serious when, based upon appropriate medical judgment, they may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition.  
 All adverse events that do not meet any of the criteria for serious , should be regarded as non- serious 
adverse events .  
 
Adverse Event Reporting Period  
 
For this study, the study treatment follow -up period is defined as t hree ( 3) days following the last 
administration of study treatment, based on 2 hour half- life of  EPI.  
 Preexisting Condition 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 29 of 49                                  CONFIDENTIAL  
 A preexisting condition is one that is present at the start of the study.  A preexisting condition should 
be recorded as an adverse event if the frequency, intensity, or the character of the condition worsens during the study period.  
General Physical Examination Findings 
At screening, any clinically significant abnormality should be recorded as a preexisting condition.  
At the  end of the study, any new clinically significant findings/abnormalities that meet the definition 
of an adverse event must also be recorded and documented as an adverse event.  
 
Post-study Adverse Event  
All unresolved adverse events should be followed by t he sponsor-investigator until the events are 
resolved, the subject is lost to follow-up, or the adverse event is otherwise explained.  At the last scheduled visit, the sponsor-investigator should instruct each subject to report, to the sponsor-investigator  any subsequent event(s) that the subject, or the subject’s personal physician, b elieves 
might reasonably be related to participation in this study.   
 
Abnormal Laboratory Values 
A laboratory abnormality should be documented as an adverse event if the laboratory value remains 
outside of the normal range on repeat testing and the subject’s personal physician or PI, believe might reasonably be related  to study medication.  If the subject’s personal physician or PI considers 
the laboratory abnormality unsa fe/clinically significant, the study treatment might be discontinued. If 
the laboratory abnormality is considered treatable, it will be treated appropriately. The laboratory abnormality will be followed until it normalizes or no longer is considered unsafe and needing a follow up.   
Hospitalization, Prolonged Hospitalization or Surgery 
Any adverse event that results in hospitalization or prolonged hospitalization should be documented 
and reported as a serious adverse event unless specifically instructed otherwise in this protocol.  Any condition responsible for surgery should be documented as an adverse event if the condition meets the criteria for an adverse event.   
8.2 Recording of Adverse Events  
During each contact with the subject, the study team will seek information on adverse events by 
specific questioning and, as appropriate, by examination.  Information on all adverse events should be recorded in the source document, and also in the appropriate adverse event section  of the case 
report form (CRF) or in a separate adverse event worksheet . All changes in symptoms, and 
diagnostic, laboratory or procedure results that potentially are considered related to study medication  
should recorded in the source documents.  The subject’s AE diary will be considered  a study source 
document and retained by the site within the subject’s study file for monitoring and inspectional purposes.  All adverse events occurring during the study period will be recorded.  The clinical course of each event will be followed until resolution, stabilization, or until it has been ultimately determined that the study treatment or participation is not the  probable cause.  Serious adverse events that are still 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 30 of 49                                  CONFIDENTIAL  
 ongoing at the end of the study period must be followed, to determine the final outcome.  Any 
serious adverse event that occurs after the study period and considered to be at least possibly related to the study treatment or study participation should be recorded and reported immediately. 
8.3 Reporting of Serious Advers e Events and Unanticipated Problems  
When an adverse event has been identified, the study team will take appropriated action necessary to 
protect the study participant and then complete the Study Adverse Event Worksheet and /or log.  The 
sponsor-investigator will evaluate the event and determine the necessary follow -up and reporting 
required.  
8.3.1 Sponsor -Investigator reporting: notifying the Mayo IRB 
The sponsor-investigator will report to the Mayo IRB any UPIRTSOs and Non- UPIRTSOs 
according to the Mayo IRB Policy and Procedures.  The sponsor- investigator will review all adverse event reports to determine if specific reports need to 
be made to the IRB and FDA.  The sponsor-investigator will sign and date the adverse event report when it is reviewed.  For this protocol, only directly related SAEs /UPIRTSO s will be reported to the 
IRB.  
8.3.2 Sponsor -Investigator reporting: Notifying the FDA 
The sponsor- investigator will report all unexpected, serious suspected adverse reactions to the FDA 
according to the required IND Safety Reporting timelines, formats and requirements.  
 Unexpected fatal or life threatening suspected adverse reactions where there is evidence to suggest a causal relationship between the study drug/placebo and the adverse event, will be reported as a serious suspected adverse reaction.  This will be reported to the FDA on FDA Form 3500A, no later than 7 calendar days after the sponsor- investigator’s initial receipt of the information about the 
event.  
 Other unexpected serious suspected adverse reactions where there is evidence to suggest a causal relationship between the study drug/placebo and the adverse event, will be reported as a serious suspected adverse reaction.  This will be reported to the FDA on FDA Form 3500A, no later than 15 calendar days a fter the sponsor-investigator’s initial receipt of the information about the event. 
 Any clinically important increase in the rate of serious suspected adverse reactions over those listed in the protocol or product insert will be reported as a serious suspected adverse reaction.  This will be reported to the FDA on FDA Form 3500A no later than 15 calendar days after the sponsor-investigator’s initial receipt of the information about the event.  
 Findings from other studies in human or animals that suggest a significant risk in humans exposed to the drug will be reported.  This will be reported to the FDA on FDA Form 3500A, no later than 15 calendar days after the sponsor- investigators initial receipt of the information about the event.  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 31 of 49                                  CONFIDENTIAL  
 8.4 Stopping Rules  
 
The st udy will be halted if Serious Adverse Events which are felt by the PI to possibly be related to 
treatment with study medication occur s in 2 or more patients.  Any adverse event with the outcome 
of death that is felt caused by or possibly related to treatment with study medication will cause the 
study to be stopped. 
8.5 Medical Monitoring  
It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her site.  
This safety monitoring will include careful assessment and ap propriate reporting of adverse events 
as noted above, as well as the construction and implementation of a site data and safety-monitoring plan (see section 10  “Study Monitoring, Auditing, and Inspecting” ).  Medical monitoring will 
include a regular assess ment of the number and type of serious adverse events. 
9 Data Handling and Record Keeping  
9.1 Confidentiality  
Information about study subjects will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and w hy 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, retains the abilit y to use all information collected prior to the revocation of subject authorization.  
For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to coll ect at least vital status (long term survival status that the subject is alive) at the end 
of their scheduled study period. 
9.2 Source Documents  
Source data is all information, original records of clinical findings, observations, or other activities 
in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in source documents.  Examples of these original documents, and data records include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, subject diaries, recorded data from automated instruments, copie s or transcriptions certified after verification as being accurate and complete, 
microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and records 
kept at the pharmacy, at the laboratories, and at medico- technical departm ents involved in the 
clinical trial.  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 32 of 49                                  CONFIDENTIAL  
 9.3 Database 
Data Management 
A RedCap database will be used to collect the data intended for analysis  and entries will be available 
for review by the ORRS study monitor as well as for regulatory inspectors. 
 
Data Security and Confidentiality  
The RedCap study database will  be maintained on password protected computers, hosted on Mayo 
Clinic servers , which are backed up on a daily basis a ccording to Institutional Policies.  
 Data Quality Assurance 
Data will be extracted from source documents and entered into the study databas e. The Study 
Coordinator or study team member so delegated by the PI will assure the accuracy and integrity of 
the data and the PI will evaluate the data and the supporting source documents periodically.    
9.4 Records Retention  
The sponsor- investigator will maintain records and essential documents related to the conduct of the 
study.  These will include subject case histories and study regulatory documents. The sponsor-investigator will retain the specified records and reports for the longest of these retention periods :  
1. Up to 2 years after the marketing application is approved for the drug; or, if a marketing application is not submitted or approved for the drug, until 2 years after shipment and delivery of the drug for investigational use is discontinued and the FDA has been so notified. OR 
2. As outlined in the Mayo Clinic Research Policy Manual –“Retention of and Access to Research Data Policy”    
10 Study Monitoring, Auditing, and Inspecting  
10.1 S
tudy Monitoring Plan 
As a servi ce to the sponsor- investigator and to assist with the sponsor regulatory obligation to 
monitor study progress, this study will be periodically monitored during the conduct of the trial by 
staff from t he Mayo Clinic Office of Research Regulatory Support.  Clinical trial monitoring may 
include but will not necessarily be limited to review of the study regulatory documents , source data 
and database entries  throughout the duration of the study to help  ensure the validity and integrity of 
the data.  Original informed consent forms will be reviewed. Written monitoring reports with findings and recommended and suggested corrective actions will be provided to the sponsor. 
10.2 Auditing and Inspecting  
The investigator will permit study -related monitoring  by ORRS and audits by the IRB Compliance 
Unit, if indicated, as well as inspections by authorized representative of government regulatory 
agencies  such as FDA  of all study related documents (e.g. source documents, regulatory documents, 
data collection instruments, drug accountability records and study data etc.).  The investigato r will 

IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 33 of 49                                  CONFIDENTIAL  
 ensure access is granted for  inspection of applicable study- related facilities (e.g. pharmacy, 
diagnostic laborator ies, etc.).  
 
Participation as an investigator in this study implies acceptance of potential inspection by government regulatory authorities and applicable compliance offices.  
11 Ethical Considerations 
This study is to be conducted according to applicable U nited States  government regulations and 
Institutional researc h policies and procedures. 
 This protocol and any amendments as well as subject materials such as the informed consent/assent forms will be submitted to a properly constituted  Mayo Clinic Institutional Review Board (IRB  for 
review and  formal approval .  The decision (s) of the IRB concerning the conduct of the study will be 
made in writing to the sponsor-investigator before commencement of this study.  All subjects for this study will be provided a consent (or assent) form describing this study and providing sufficient information for subjects to make an informed decision about their participation in this study.  The formal consent of a subject, using the IRB a pproved consent  or assent  form, must 
be obtained before subject undergoes any study procedure.  The consent form must be signed and dated by the subject or the subject’s le gally authorized representative, a s well as  the i ndividual 
obtaining the informed consent. 
12 Study Finances  
12.1 Funding Source  
This study will be  financed through a grant from the Mayo C linic Children's Research Center 
Pediatric Team Science Award.    Study medication will be provided by Cardero Therapeutics. Costs 
associated with the study -specific laboratory tests performed  by UC -San Diego will be paid for by 
Cardero Therapeutics.  
12.2 Conflict of Interest  
Any study team member  who has a conflict of interest with this study (patent ownership, royalties, 
or financial gain greater than the minimum allowable by their institution, etc.) must have the conflict 
reviewed by a properly constitut ed Conflict of Interest Committee with a Committee -sanctioned 
conflict management plan that has been reviewed and approved by the study sponsor- investigator  
prior to participation in this study.  
13 Publication Plan  
This study will be registered on the  ClinicalTrials.gov  registry  prior to the first subject being 
enrolled.  Study results will subsequently be posted to the registry within 12 months of final data collection for the primary outcome measure.   
 
 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 34 of 49                                  CONFIDENTIAL  
 Study results will be analyzed and manuscripts prepared for submission to the appropriate peer-
reviewed scientific journals.  The NCT number linking to the clinicaltrials.gov record will be included in manuscripts.   
14 References  
1. DiMauro , S., et al., The clinical maze of mitochondrial neurology.  Nature reviews. Neurology, 2013. 9 (8): p. 429- 44. 
2. Parikh, S., et al., Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial 
Medicine Society.  Genetics in medicine : official journal of the American College of Medical Genetics, 2015. 17 (9): p. 689-
701. 
3. Nogueira, L., et al., (-)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle.  The Journal of 
physiology, 2011. 589 (Pt 18): p. 4615- 31. 
4. McDonald CM, H.E., Oskarsson B, Aguilar C, Nicorici A, Joyce N, Reddy D, Wagner A, deBie E, Goude E, Abresch RT, Villareal F, Perkins G, Hathout Y, Dugar S, Schreiner G., Epicatechin enhances mitochondrial biogenesis, increases 
dystrophin and utrophin, increases follistatin while decreasing myostatin, and improves skeletal muscle exercise response in 
adults with Becker muscular dystrophy (BMD).  in MDA Scientific Conference 2015 2015: Washington, DC.  
5. Ramirez-Sanchez, I., et al., (-)-Epicatechin rich cocoa mediated modulation of oxidative stress regulators in skeletal muscle 
of heart failure and type 2 diabetes patients.  International journal of cardiology, 2013. 168(4): p. 3982- 90. 
6. Taub, P.R., et al., Perturbations in skeletal muscle sarcomere structure in patients with heart failure and type 2 diabetes: 
restorative effects of ( -)-epicatechin -rich cocoa.  Clinical science, 2013. 125(8): p. 383-9.  
7. Moreno -Ulloa, A., et al., Effects of ( -)-epicatechin and derivatives on nitric oxide mediated induction of mitochondrial 
proteins.  Bioorganic & medicinal chemistry letters, 2013. 23(15): p. 4441 -6. 
8. Ruijters, E.J., et al., The flavanol ( -)-epicatechin and its metabolites protect against oxidative stress in primary endothelial 
cells via a direct antioxidant effect.  European journal of pharmacology, 2013. 715(1-3): p. 147-53.  
9. Gutierrez-Salmean, G., et al., Effects of ( -)-epicatechin on a diet -induced rat model of cardiometabolic risk factors.  
European journal of pharmacology, 2014. 728: p. 24- 30. 
10. Cordero-Herrera, I., et al., Cocoa flavonoids attenuate high glucose -induced insulin signalling blockade and modulate 
glucose uptake and production in human HepG2 cells.  Food and chemical toxicology : an international journal published fo r 
the British Industrial Biological Research Association, 2014. 64: p. 10- 9. 
11. Gutierrez-Salmean, G., et al., Effects of ( -)-epicatechin on molecular modulators of skeletal muscle growth and 
differentiation.  The Journal of nutritional biochemistry, 2014.  25(1): p. 91- 4. 
12. Nath, S., et al., Catechins protect neurons against mitochondrial toxins and HIV proteins via activation of the BDNF 
pathway.  Journal of neurovirology, 2012. 18(6): p. 445-55.  
13. Shay, J., et al., Molecular Mechanisms and Therapeutic Effects of ( -)-Epicatechin and Other Polyphenols in Cancer, 
Inflammation, Diabetes, and Neurodegeneration.  Oxidative medicine and cellular longevity, 2015. 2015 : p. 181260.  
14. Portella Rde, L., et al., Guarana (Paullinia cupana Kunth) effects on LDL oxidation in elderly people: an in vitro and in vivo study.  Lipids in health and disease, 2013. 12 : p. 12.  
15. Duchan, E., N.D. Patel, and C. Feucht, Energy drinks: a review of use and safety for athletes.  The Physician and 
sportsmedicine, 2010. 38 (2): p. 171 -9. 
16. Puccio, H. and M. Koenig, Friedreich ataxia: a paradigm for mitochondrial diseases.  Current opinion in genetics & 
development, 2002. 12 (3): p. 272 -7. 
17. Vaubel, R.A. and G. Isaya, Iron -sulfur cluster synthesis, iron homeostasis and oxidative stress in Friedreich ataxia.  
Molecular and cellular neurosciences, 2013. 55: p. 50 -61. 
18. Shah, Z.A., et al., The flavanol ( -)-epicatechin prevents stroke damage through the Nrf2/HO1 pathway.  Journal of cerebral 
blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2010. 30(12): p. 1951- 61. 
19. Tao, L., J.Y. Park, and J.D. Lambert, Differential prooxidative effects of the green tea polyphenol, ( -)-epigallocatechin -3-
gallate, in normal and oral cancer cells are related to differences in sirtuin 3 signaling.  Molecular nutrition & food 
research, 2015. 59(2): p. 203-11.  
20. Barnett, C.F., et al., Pharmacokinetic, partial pharmacodynamic and initial safety analysis of ( -)-epicatechin in healthy 
volunteers.  Food & function, 2015. 6 (3): p. 824-33.  
21. Ottaviani, J.I., et al., The stereochemical configuration of flavanols influences the level and metabolism of flavanols in 
h
umans and their biological activity in vivo.  Free radical biology & medicine, 2011. 50(2): p. 237-44.  
22. Actis -Goretta, L., et al., Elucidation of ( -)-epicatechin metabolites after ingestion of chocolate by healthy humans.  Free 
radical biology & medicine, 2012. 53 (4): p. 787-95.  
23. J, G., Report: Cytochrome P450 (Cyp) inhibition assay: To evaluate the effect of Test Article SPR590 (coded as SPE149) on 5 Cytochrome P450 (Cyp) enzymes 3A4, 1A2, 2D6, 2C19 and 2C9 in human liver microsomes. , 2015, Advinus Therapeutics 
Limited. p. 1.  
24. Hawryluk, P., HERG -Lite Assay:Effect of Test Article on Clo ned hERG Channel Surface Expression in Mammalian Cells , 
2015, ChanTest A Charles River Company. p. 1- 3. 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 35 of 49                                  CONFIDENTIAL  
 25. Sen, S., Data Report for Pharmacology Services , 2015, Eurofins Panlabs Taiwan, Ltd.: Taipei, Taiwan. p. 1 -43. 
26. Ramirez-Sanchez, I., et al., (-)-E picatechin improves mitochondrial -related protein levels and ameliorates oxidative stress 
in dystrophic delta -sarcoglycan null mouse striated muscle.  The FEBS journal, 2014. 281(24): p. 5567- 80. 
27. Moreno -Ulloa, A., et al., Recovery of Indicators of Mitochondrial Biogenesis, Oxidative Stress, and Aging With ( -)-
Epicatechin in Senile Mice.  The journals of gerontology. Series A, Biological sciences and medical sciences, 2015. 70(11): 
p. 1370 -8. 
28. Taub, P.R., et al., Alterations in skeletal muscle indicator s of mitochondrial structure and biogenesis in patients with type 2 
diabetes and heart failure: effects of epicatechin rich cocoa.  Clinical and translational science, 2012. 5 (1): p. 43 -7. 
29. Zhang, Q., et al., Catechin ameliorates cardiac dysfunction in rats with chronic heart failure by regulating the balance 
between Th17 and Treg cells.  Inflammation research : official journal of the European Histamine Research Society ... [et 
al.], 2014. 63(8): p. 619-28.  
30. Yamazaki, K.G., et al., Effects of ( -)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent 
coronary occlusion.  Journal of the American College of Cardiology, 2010. 55(25): p. 2869 -76. 
31. Malik, V., L.R. Rodino -Klapac, and J.R. Mendell, Emerging drugs for Duchenne  muscular dystrophy.  Expert opinion on 
emerging drugs, 2012. 17(2): p. 261- 77. 
32. Huttemann, M., I. Lee, and M.H. Malek, (-)-Epicatechin maintains endurance training adaptation in mice after 14 days of 
detraining.  FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2012. 
26(4): p. 1413 -22. 
33. Leonardo, C.C., et al., Oral administration of the flavanol ( -)-epicatechin bolsters endogenous protection against focal 
ischemia through the Nrf2 cytoprotective pathway.  The European journal of neuroscience, 2013. 38 (11): p. 3659- 68. 
34. Dower, J.I., et al., Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: 
a randomized,  double -blind, placebo-controlled, crossover trial.  The American journal of clinical nutrition, 2015. 101(5): p. 
914-21. 
35. Oglesbee, D., et al., High -throughput immunoassay for the biochemical diagnosis of Friedreich ataxia in dried blood spots 
and whole  blood.  Clinical chemistry, 2013. 59 (10): p. 1461- 9. 
36. Lynch, D.R., et al., A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial.  Movement 
disorders : official journal of the Movement Disorder Society, 2012. 27 (8): p. 1026 -33. 
37. Gibb, C.M., et al., Chocolate is a migraine -provoking agent.  Cephalalgia : an international journal of headache, 1991. 11(2): 
p. 93 -5. 
38. Katz, D.L., K. Doughty, and A. Ali, Cocoa and chocolate in human health and disease.  Antioxidants & redox signaling, 
2011. 15(10): p. 2779 -811.  
39. Rein, D., et al., Cocoa inhibits platelet activation and function.  The American journal of clinical nutrition, 2000. 72(1): p. 
30-5. 
40. Ramirez-Sanchez, I., et al., (-)-epicatechin activation of endothelial cell  endothelial nitric oxide synthase, nitric oxide, and 
related signaling pathways.  Hypertension, 2010. 55(6): p. 1398- 405. 
41. Ried, K., et al., Does chocolate reduce blood pressure? A meta- analysis.  BMC medicine, 2010. 8 : p. 39.  
42. Mattei, R., et al., Gua rana (Paullinia cupana): toxic behavioral effects in laboratory animals and antioxidants activity in 
vitro.  Journal of ethnopharmacology, 1998. 60 (2): p. 111 -6. 
43. Sen, S., Evaluation of ‘Repeat Dose Tolerability’ of SPR590 at a dose of 100mpk for 10 days  by oral administration, in 
Sprague Dawley (SD) rats. , 2015, Sphaera Pharma Private Limited. p. 1 -15. 
44. de Oliveira Campos, M.P., et al., Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing 
systemic chemotherapy.  Journal of a lternative and complementary medicine, 2011. 17(6): p. 505-12.  
45. Coppola, G., et al., Functional genomic analysis of frataxin deficiency reveals tissue -specific alterations and identifies the 
PPARgamma pathway as a therapeutic target in Friedreich's atax ia. Human molecular genetics, 2009. 18(13): p. 2452 -61. 
46. Shan, Y., et al., Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia 
of the Friedreich's ataxia YG8R mouse model.  Antioxidants &  redox signaling, 2013. 19(13): p. 1481-93.  
47. Wagner, G.R., et al., Friedreich's ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via 
f
eedback inhibition of the SIRT3 deacetylase.  Human molecular genetics, 2012. 21(12): p. 2688- 97. 
 
15  Attachments 
15.1  Attachment  I  Friedreich’s Ataxia Rating Scale (FARS)  
15.2  Attachment  II  Protocol Schedule of Events 
 
 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 36 of 49                                  CONFIDENTIAL  
   
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 37 of 49                                  CONFIDENTIAL  
 Attachment I  
Friedreich's Ataxia Rating Scale  
 
NINDS  CDE N otice of Copy right 
Friedreich Ataxia Rating Scale (FARS) 
 
Availability: The  instrument  is  freely  available  here:  http://www.ataxia-study- 
group.net/ html/about /ataxiascale s/fars 
Classification: Core 
Short Description 
of Inst rument: The Friedreich Ataxia  Rating Scale  (FARS) is made up of a measure of ataxia,  an 
activities of daily living subs cale and a neurolog ical s ubscale.  This scale also i ncludes 
the 8m walk at maximum speed (8M W), the 9-hole  peg test (9HPT), and low-contr ast 
letter acuit y.  
Strengths: FARS scores corre late significa ntly with f unctional d isability, acti vities of 
daily living scores and dis ease du ration.  FA RS h as a lar ge effect size and requ ires fewer 
patients for an e quivalently  powere d study.  
Wea knesses: This scale captures a particular dimension of neurolog ic function in FA , 
so as a composite  measure, it is not good enoug h to pre dict d isease stat us. 
Scoring: The scores from the three subscales  are added to generate a total score ranging from 0 to 
159, with a hi gher score i ndicati ng a greater level of disa bility.  
Functional Staging for Ataxia subscale sco ring: 0 = Norm al - 6.0 = Confi ned to 
wheelc hair or bed with  total depe ndency for all A DL. Total  disability.  
ADL subsc ale sco ring: 9 items scored from 0 to  4.  
Neurolog ical Examinat ion sub scale scori ng: 5 items scored from 0 to 2 or 0 to 5, 
depending on the spe cific parame ter. 
References: Key Reference:  
Subramony SH , May W, Lynch D, et al.  Measuring Friedreich ataxi a: inte rrater 
reliability of a neurolog ic rating scal e. Neurology. 2005;64:1261–2.  
Other Refer ences:  
Delatycki MB. Evaluating the progre ssion of Friedre ich ataxia a nd its treat ment. J 
Neurol. 2009. 256( Suppl 1):36-41.  
Fahey M C, Corben L, Collins V, C hurchyard AJ , Delatycki MB. How is disease 
progre ss in Friedre ich’s ataxia be st measured? A st udy of four ra ting scales. J Neurol 
Neurosu rg Psychiatr. 2007 Apr; 78(4):4113- 413.  
Lynch DR, Farme r JM, Tsou A Y, Perlman S, Sub ramony SH , Gome z CM, Ashiz awa 
T, Wilmot GR, Wil son R B, Balcer LJ. Measuring F riedrei ch ataxi a: 
comple mentary features of examinat ion and performance measures. Neu rology. 
2006 Jun 13; 66(11) :1711-6.  
Subramony SH , May W, Lynch D, Go mez C, Fischbeck K et al. Me asuring 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 38 of 49                                  CONFIDENTIAL  
  Friedreich at axia: Interrater reliability of a neurologic rating scale. Neurology 
2005;64:1261-1262. 
 
Lynch DR, Farme r JM, Tsou A Y, Perlman S, Sub ramony SH et al.  Measuring 
Friedreich at axia: complementary  features of examina tion and performance me asures. 
Neurology 2006; 66:1711-1716. 
  
Short Description 
of Inst rument:  
Scoring:  
References:  
 The Nine Hole Pegboard Test 
Short Description 
of Inst rument: Construct measured:  Upper extremity function 
Generic vs. d isease specific: Gene ric 
Mean s of administration : In pe rson by a trained examiner  
Intende d res ponden t:  Patient 
#  of items: N/A 
# of subscales an d names o f sub-scales: N/A 
# of items per sub-scale: N/A 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 39 of 49                                  CONFIDENTIAL  
  Scoring: Both the dominant and non-dominant hands are tested twice within a 
single testing session. T he total  time to comple te the t ask is recorded. T he sco re for the 9-
HPT is  an average of t he four trials.  The two trials  for e ach hand are  averaged, con verted 
to the re ciprocals of the mea n times for each hand an d then the two re ciprocals are 
averaged. T his score  can be used individu ally or use d as part of the M SFC composi te 
score.  
Backgr ound :  The 9-HPT is  a brief, stand ardized, quantitati ve te st of upper extr emity 
function. It  is the se cond component of the M SFC to be adminis tered at  each visit. Both 
the do minant and non-dominant ha nds are tested twice. Two c onsecu tive trials  with the 
dominant hand are  immediately followed by tw o consec utive trials  with the non-dominant 
hand. 
Psychometric 
Propertie s: Strengths/Wea knesses:  There has been increasing recognition of the usefulness of  
measuri ng arm and hand f unction in cli nical st udies. The 9-HPT is one of t he mo st 
frequen tly used measures o f upper  extremity funct ion in MS. I t is responsive to changes 
at the upp er level of pe rformance but not whe n impair ment is  severe.  
Psyc hometric Pr operties: The 9-HPT has hig h inter-rate r reliability and good test -
retest re liability. The re is evidence for concu rrent and c onvergent v alidity as well as 
sensiti vity to dete ct minor impai rments  of hand fun ction.  P erformance  on the 9-Hole  
Peg Test may be sensiti ve to practice effects, that is, patie nts often display poore r 
performance  whe n first tested due to la ck of fa miliarity wi th the task.  It is recommended 
that three or four adminis trations be gi ven prior to a baseline assess ment if accu rate 
(rather than comparative ) assessmen ts of change ove r time are n eeded.  
Admi nistration :  The 9HPT is  adminis tered in person by a t rained examiner, who need 
not be a physician or nu rse. Adminis tration time v aries depe nding upon t he ab ility of 
the p atient, but typical ly total a dministra tion time is a pproxim ately 10 minutes or le ss. 
 Low Contrast Letter Acuity 
Short Description 
of Inst rument: Construct measured:  Low contrast letter acuity 
Generic vs. d isease specific: Gene ric Mean s 
of admin istrati on: Assess ment Int ende d 
respondent :  Patient 
#  of items: N/A 
# of subscales an d names o f sub-scales: N/A  
# of items per sub-scale: N/A 
Scoring:  Scoring: Charts are scored based on the number of letters identified correctly.  
This format provides continuous scoring and may allow Sloan charts to capture losses 
of contrast at small letter sizes.  
 
Background: Low contrast acuity testing provides information on patient- reported 
aspects of vision. This testing is performed using low -contrast Sloan letter charts. Each 
chart corresponds to a different contrast level (shade of gray letters on 
white/retroilluminated background).  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 40 of 49                                  CONFIDENTIAL  
 References:  Key Refe rence: Balcer LJ, et al. Contrast letter acuity as a visual component for  the 
Multiple Sclerosis Functional Composite. Neurol. 2003; 61:1367-73.  
 
Other References:  
Balcer LJ, et al. New low -contrast vision charts: reliability and test characteristics in 
patients with multiple sclerosis. Mult Scler June 2000;  
6(3):163-171.  
Psychometric  
Properties: Strengths/ Weakne sses: Sloan charts have a standardized format based on  
Early Treatment Diabetic Retinopathy Study visual acuity charts, which are the standard used for ophthalmology clinical trials. 
 
Psychometric Properties: Inter -rater agreement was described with the intraclass 
correlation coefficient (ICC) and comparison of mean scores. Excellent inter -rater 
agreement (ICC=0.86 -0.95) was demonstrated at each contrast level among MS 
patients (n=100) and visually- asymptomatic volunteers (n=33). Ave rage letter scores at 
the lowest contrast level (0.6%) were highly variable in the MS group, even among 
patients with visual acuities of 20/20 or better, and among those who required no 
assistance for ambulation.  
 
 
              
           
 
 
  
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 41 of 49                                  CONFIDENTIAL  
 SUPP LEMENTAL DATA :  E - APPEND IX I (E)A-1 ): RATING SCALE FOR F RIEDRE ICH’S ATAX IA 
 
 
I.  FUNCTIONAL STAGING  FOR A TAXIA 
 
Increment by 0 .5 may be us ed if the status is ab out the mi ddle between  two stages. 
 
STAGE 
 
STAG E  0:  Nor mal. 
 
STAG E  1.0:  Minimal signs detected  by physician during sc reening.  Can run o r jump w ithout loss o f 
balan ce. No disabili ty. 
 
STAG E  2.0:  Sympto ms present, recognized by patient, but still mild.  Can not run o r jump withou t losing 
balan ce.  The pa tient is phy sically capable of leading an independent life, but dail y activities 
may be somewhat re stricted .  Minimal disa bility. 
 
STAG E  3.0:  Sympto ms are overt and sign ificant.  Requires regul ar or periodic h olding onto wall/furnitu re 
or use of a cane for stability and walki ng.  Mild disab ility. ( Note: many patie nts postpone 
obtaining a cane by avoiding op en spaces and walking wit h the aid o f walls/ people etc.  These 
patients are grades as stage 3.0) 
 
STAG E  4.0:  Walking requires  a walker, Canadian  crutches or two canes .  Or oth er aids su ch as 
walking dogs. Can perform several activities of daily living .  Moderate d isability. 
 
STAG E  5.0:  Confin ed but can navigate a wh eelchair.  Can perform some activities of daily li ving tha t do not 
require standing or wa lking.  Severe disab ility. 
 
STAG E  6.0:  Confin ed to wheelchair or b ed with total dependency for all activities of daily li ving. 
Total disa bility. 
 
 
II.   ACTIVITIES OF DAILY LIVING  (in crements of 0 .5 may be us ed if stro ngly felt that a task falls between  
2 scores) 
 
1.  S peech 
 
0 - Normal 
1 - Mildly affected .  No difficulty being und erstood. 
2 - M oderately af fected .  Some times asked to repeat statem ents. 
3 - Severely affected .  Frequently ask ed to repeat stat ements. 
4 - Unintelli gible most of the tim e. 
 
2.  Sw allowing 
 
0 - Nor mal. 
1 - Rare  choking (< once a month ). 
2 - Frequent choking (< once a week, > once a m onth). 
3 - Requires m odified food or c hokes multiple times a w eek. Or pa tient avoid s certain 
foods. 
4 - Requires NG t ube  or gastrosto my feedings. 
 
3.  Cutting Food and Hand ling Utensils 
 
0 -  No rmal. 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 42 of 49                                  CONFIDENTIAL  
 1 -  So mewhat slow and clumsy, but no help needed. 
2 -  Clumsy and slow, but can cut most foods with so me help n eeded. Or n eeds assistance when in  
      a hurry. 
3 -  F ood m ust be cut by some one, but can still feed self slowly. 
4 -  Needs to be fed. 
 
4.  D ressing 
 
0  -  Normal. 
1  -  So mewhat slow, but no help n eeded. 
2 -  Occasion al as sistan ce with buttoning, ge tting ar ms in sleeves, etc.  or has to modif y 
activity in so me way (e.g. Having to sit to g et dressed; use velcro  for shoes, stop 
wearing ties, etc. ). 
3  -  Consid erable help re quired, but can do so me things alon e. 
4  -  Helpless.  
 
5.    Personal H ygiene 
 
0 -  No rmal. 
1 -  So mewhat slow, but no help n eeded. 
2 -  Very slow h ygienic care or h as need for devices such as special gr ab bars, tu b bench, 
shower  chair,  etc. 
3 -  Re quires personal help with washing, brushing teeth, combing hair or u sing toi let. 
4 -  Fully depe ndent 
 
6.  Falling (a ssistive devi ce = sco re 3) 
 
0 -  No rmal. 
1 -  R are falling (< on ce a month ). 
2 -  Occasion al falls (on ce a w eek to on ce a m onth). 
3 -  Falls mu ltiple times a week or requires devi ce to p revent falls. 
4 -  Unable to stand or walk. 
 
7.  Walking  (assistive device = sco re 3) 
 
0 -  No rmal. 
1 -  Mild difficulty, percep tion of imbalance. 
2 -  Moderate difficu lty, but requires  little or no as sistance. 
3 -  Sev ere disturban ce of walking, requires a ssistan ce or walking aids. 
4 -  Ca nnot walk at all ev en with assistan ce (wheelchair b ound ). 
 
8.  Quality of Sitt ing Position 
 
0 -  No rmal. 
1 -  Sligh t imbalance of th e trunk, but n eeds no b ack support. 
2 -  Unable to sit without b ack support. 
3 -  C an sit only w ith exten sive suppo rt (Ger iatric chai r, posy, etc. ). 
4 -  Unable to s it. 
 
9.  Bladder  Function (if using  drugs for bla dder,  automatic score of 3) 
 
0 -  No rmal. 
1 -  Mild urinary hesitan ce, urgency or retention (< once a month ). 
2 -  Moderat e  hesitan ce, urgency, rare retentio n/incontinence  (> once a month , but < on ce 
a week ). 
3 -  Frequent urinar y incon tinence (> once a w eek). 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 43 of 49                                  CONFIDENTIAL  
 4 -  Loss o f bladder function requiring inte rmittent catheter ization/indwellin g catheter. 
 
                         TO TAL ACTIVITIES  OF DAILY LIVING SCORE : 
 
 
III.  NEUROLOGICAL EXAMINATION (rate each item on the ba sis of the patient status during examination. 
To the extent possible,  sequen tial patient ex aminations s hould be carried out at the sa me time  of the day. If th e patient 
is taking an y me dication, the ex amination sh ould be c arried  out prior to dosi ng, or at a fix ed time following the dosing 
based on th e maximum exp ected th erapeu tic respons e.  Increm ents of 0 .5 may be us ed if examiner feels an item falls 
betw een 2 defined sev erities) 
 
A.  BULBAR 
 
1.  Facial Atrophy, Fasciculatio n, Action Myo clonus, a nd Weakness: 
 
0  -  None 
1  -  Fascicula tions or ac tion myocl onus, but no atr ophy. 
2  -  Atrophy p resent but not profound or complete.  
3  -  Profound atr ophy and weakne ss. 
 
2.   Tong ue Atrophy, Fasciculation, Action Myo clonus and Weakness: 
 
0  -  None.  
1  -  Fascicula tions or ac tion myoclonus, but no atr ophy. 
2  -  Atrophy p resent but not prof ound or complet e. 
3  -  Profound atr ophy and weakne ss. 
 
3.  Coug h:  (Patient ask ed to cough fo rcefully 3 times) 
 
0 - Nor mal. 
1 - Depre ssed. 
2 - Totally or nearly absent. 
 
4.  Spontaneous Speech  (ask the patient to read or repeat the senten ces "The President lives in the White House" 
or "The traff ic is h eavy tod ay": 
 
0 - Nor mal. 
1 - Mild (all or most words und erstandabl e). 
2 - M oderate (most words not understandable).  
3 - Severe (no or almost no useful sp eech).  
 
                TO TAL BULBAR  SCORE: 
 
B.  UPPE R LIMB  COORDINATION 
 
1.  Fing er to Fing er Test (The ind ex fingers are plac ed in front of each other with flexion at th e elbow a bout 
25 cm. from the sternum .  Observe for 10 seconds. Score amplitude o f oscillations ): 
  
           
    Right              Left 
0  -  Normal. 
1  -  Mild oscillations of fing er (< 2 cm. ). 
2  -  M oderate oscill ations of fing er (2-6 cm.). 
3  -  Severe oscillations of fing er (> 6 cm.). 
 
2.    Nose- Finger Test ( Assess kine tic or inten tion tremor during and towards the end o f movement: examiner 
holds ind ex fing er at 90% reach  of patie nt; test at least 3 nose-fing er-nose trials ; movement slow > 3 sec .): 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 44 of 49                                  CONFIDENTIAL  
  
              Right                 L eft 
0  -  None 
1  -  M ild (< 2 cm. amplitude). 
2  -  M oderate (2-4 cm. amplitude or persi sting through m ovement ). 
3  -  Severe (> 6 cm. & per sisting through movement).  
4  -  Too poorly coordinated  to perform task. 
 
3.   Dysmetria (Fast Nose-Fi nger) Test:  (Ass ess dysmetria: The pa tient touches tip of ex aminer’ s finger 8 
times as rap idly as possible while the ex aminer mov es his fing er and stops at differen t locations at a bout 
90% reach  of the patient. Assess dysmetria – i .e. inaccuracy of reaching th e target- at examine r’s finger): 
 
     
         Right                L eft 
0  -  None.  
1  -  Mild (misses 2 or fewer time s). 
2  -  M oderate (m isses 3-5 times). 
3  -  Severe (misses 6-8 times. ). 
4  -  Too poorly coordinated  to perform task. 
 
4.  Rapid  Alternating Movem ents  of Ha nds  (For earm  prona tion/supination 15 cm. a bove thigh; 1 0 full cycl es 
as fast as pos sible; assess rate,  rhyth m, accuracy; p ractice 10 cycles  before rating, i f time > 7 s ec. add 1 to 
score. Use stopwatch): 
              Right                 L eft 
0 - Nor mal. 
1
 - Mild (slightly irregular  or slowed). 
2 - M oderate (i rregular and slowed ). 
3 – Too poorly coordinat ed to perform task. 
 
5.   Fing er Taps (ind ex fingertip-to-thu mb crease; 15 reps as fast as possible; p ractice 15 reps on ce before 
rating; if time > 6 se c., add 1 to rating. Use sto pwatch): 
                                                                                                                                                        Right                Left  
0 - Nor mal. 
1 - Mild (misses 1-3 times ). 
2 - M oderate (misses 4-9 times). 
3 - Severe (misses 10-15 times ). 
           4 - Cannot p erform th e task. 
 
TOTAL UPPER  LIMB  COORDINATI ON SCORE 
 
 
C.  LOWER LIMB COORDINATION 
 
1.  Heel  Along Shin Slide (und er visual c ontrol, s lide heel on the contralateral tibia from the patell a to the 
ankle up and d own, 3 cycl es at moderate sp eed, 2 sec./cycl e, one at a time. May be s eated with 
contralateral leg  extended or su pine but p erform same way each time. Circ le which: s upine seated ): 
 
0 - Nor mal (stay on s hin).             Right             L eft 
1 - Mild (abnorma lly slow, tremulous but c ontact maintained ). 
2 - M odera te (go es off shin a total of 3 or fewer times during 3 cycles ). 
3 - Severe (goes off shin 4 or mo re times during 3 cycles ). 
4 - Too poorly coordinated  to attempt the task. 
 
2.  Heel-to- Shin Tap (patient taps h eel on midpoint of contra lateral  shin 8 ti mes on each side from  about 
6-10", one at a time. Ma y be seated  with contralate ral leg extended  or supine but p erform the s ame 
way each time. Circle which: s upine   seated ): 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 45 of 49                                  CONFIDENTIAL  
  
0 - Nor mal (stays on t arget).             Right             L eft 
1 - Mild (misses shin 2 or < times). 
2 - M oderate (misses shin 3-5 ti mes). 
3 - Severe (misses shin > 4 times). 
4 - Too poorly coordinated  to perform task.  
     TO TAL LOW ER LIMB COORDINATION SCORE 
D. PERIPHERAL NERVOUS SYS TEM 
 
1.  Muscle Atrophy (score most severe atrophy in e ither u pper or lower  limb): 
            Right              L eft 
0 - None.  
1 - P resent - mild/m oderate 
2 - Severe/total was ting 
 
2.  Muscle Wea kness  (Test de ltoids, interossei, iliopsoas and tibialis anterior. Score most 
severe wea kness in e ither upper or low er limb): 
 
0 - Nor mal (5/5).                                                                                   Right                L eft 
1 - Mild (movement agai nst resist ance but not full power  4/5). 
2 - M oderate (movement against gra vity but not w ith added  resistan ce 3/5) 
3 - Severe (movement of joint but not against g ravity 2/5). 
4 - Ne ar paralysis (muscul ar activity without mov ement 1/5). 
5 - Total paralysis (0/5 ). 
 
3.      Vibratory Sense (E ducate patient regarding the sensation. Te sted with 128 cps t uning fo rk set t o near full 
vibration; ey es closed; test ov er index fing er and g reat toe. Abnormal < 15 seconds fo r toes and <25 s econds 
for hands): 
 
  R
ight               L eft 
Time felt for toes:    
 
Time felt for fing ers:    
 
0 - Nor mal.            Right             L eft 
1 - Impaired  at toes. 
2 - Impaired  at toes or fing ers. 
 
 
4.  Position Sense  (test using minimal random m ovement of distal interphalang eal joints of index finger 
and big to e) 
 
0 - Nor mal.            Right             L eft 
1 - Impaired  at toes/or fing ers. 
2 - Impaired  at toes and fingers. 
 
 
5.  DTR  (0-absent; 1 -hy poref lexia; 2 -no rmal; 3 -hyp erreflexia; 4 -pathologic  hyperreflexia)  
 
 Right:  
 BJ______ BrJ______ KJ______ AJ______ 
 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 46 of 49                                  CONFIDENTIAL  
  Left:  
 BJ______ BrJ______ KJ______ AJ______ 
               Right            Left 
 0 - No areflexia 
 1 - Areflexia in either upper or lower limbs.  
 2 - Generalized areflexia.  
 
                                      TOTAL PERIFPHERAL NERVOUS SYSTEM SCORE  
  
E.  
UPRI GHT  STABILI TY (For sitti ng posture patient can sit in a chair or ex amination table.  For standing and 
walki ng assessment instru ct patient to wear  best walking s hoes and record below if barefoot, footwear  or AFOs 
used.  Stan ce assess ment begins w ith feet 20 cm apart.  Place m arker tapes in th e exam room 20 cm apart and the 
insides of the feet are lined up agai nst thes e.  Subsequen t stance tests g et more difficul t.  For feet togeth er the 
entire  inside of the feet shoul d be close t ogether as much as p ossible.  For ta ndem  stance, the dominant foot is in 
the b ack and the heel o f the other foot is lined with the toes of the dominant foot but not in front of the toes 
(because this mak es it even more difficul t).  For one foot stan ce, the patient is ask ed to stand on dominant foot and 
the other l eg is elevat ed by brin ging it forward wit h knee exte nded ; this gives some advantage to the pa tient.  If a 
patient can stand i n a part icular pos itio n for 1 minute or lo nger in trial 1, the trials 2 and 3 are abandoned.  
Other wise each of 3 trials is timed and then averaged .  Grading sco res are then giv en as noted .  Tandem  walk and 
gait are perform ed in a hallway .  Preferably no carpet but at least serial examinations s hould b e on th e same 
surfa ce.  For gait place m arkers 25 feet apart .  Patient walks the d istance turns around and com es back and the 
activity is timed .  Note if th e gait w as achi eved with or without devi ce and serial ex aminations should be done 
with the same device as in the firs t examination. 
 
Stance
 and gait tests m ay be done barefoot if patient do es have appropriate footw ear, however, it should be 
done the sa me way for serial measu rement.)  
 
Circle which:  Baref oot      F ootwear 
 
Also, indicate if AFOs are used:  Yes   No 
 
1.  Sitt ing Posture (Patient s eated in chair with thighs together, arms  folded, b ack 
unsuppo rted; obs erve for 30 s ec.): 
 
0  -   Normal. 
1  -   Mild osc illations of h ead/trunk wit hout tou ching chair b ack or side. 
2  -   Moderate oscillations of h ead/trunk; n eeds c ontact with chair b ack or side fo r stability. 
3  -   Seve re  oscillations of head/trunk; n eeds contact with chair b ack or side for 
stability. 
4  -  Support on all 4 sides for stability. 
 
2.  Stance feet apart– Inside of feet 20 cm apart mark ed on floo r. Use stopwatch ; 3 attempts; 
time in s econds): 
 
Trial 1  Trial 2  Trial 3           AVG 
 
 
0 - 1 minute o r longer. 
1 - <1 minute,  >45 s ec. 
2 - <45 s ec., >30 s ec. 
3 - <30 s ec., >15 s ec. 
4 - <15 s ec. or n eeds hands held by a ssistant/device. 
 
3.  Stance
 - Feet Together (use stopwatch; 3 attempts; time in s econds): 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 47 of 49                                  CONFIDENTIAL  
  
Trial 1  Trial 2                  Trial 3                     AVG 
 
0  -  1 minute or long er. 
1  -  <1 minut e, >45 s ec. 
2  -  <45 s ec., >30 s ec. 
3  -  <30 s ec., >15 s ec. 
4  -  <15 s ec. 
 
4.  Tandem  Stance (use stopwatch; 3 attempts, dominant foot in front; ti me in  seconds ): 
 
Trial 1  Trial 2                  Trial 3                        AVG 
 
 
0  -  1 minute or long er. 
1  -  <1 minut e, >45 s ec. 
2  -  <45 s ec., >30 s ec. 
3  -  <30 s ec., >15 s ec. 
4  -  <15 s ec. 
 
5.  Stance on Dominant Foot (use sto pwatch; 3 a ttempts ; time  in seconds): 
 
Tria
l 1  Trial 2                  Trial 3                       AVG 
 
 
0  -  1 minute or long er. 
1  -  <1 minut e, >45 s ec. 
2  -  <45 s ec., >30 s ec. 
3  -  <30 s ec., >15 s ec. 
4  -  <15 s ec. 
 
6.  Tandem  Walk (tandem  walk 10 steps in straigh t line; perfor med in ha llway with no fur niture within reach of 
1 m / 3 ft. and no l oose carpet): 
 
0  -  Normal (able to tandem walk >8 sequen tial steps). 
1  -  Able to tandem  walk in < perfect ma nner/ can tandem walk >4 se quential steps ,  
       but  <8. 
2  
-  Can tand em walk, but fewer  than 4 steps before los ing balan ce. 
3  -  Too poorly coordinated  to attempt task. 
 
7.  Gait (use stopwatch; walk 8 m/25 ft. at normal pace, turn around using single step  pivot an d return to star t; 
performed in hallway w ith no furn iture within reach of 1 m/3 ft. and no loos e car pet): 
 
Devi ce, if any:   
 
    Time in seco nds:  ______  
 
0 - Nor mal. 
1 - Mild ataxia/v eering/diffic ulty in turning; no cane/other s uppo rt needed to be s afe. 
2 - Walks w ith definite ataxia; may n eed interm ittent s upport/or ex aminer n eeds to walk with patient fo r 
safet y sake. 
3 - M oderate ataxia/v eering/difficulty in turning; walki ng requi res cane/h olding onto examiner 
with one hand to be sa fe. 
4 - Severe ataxia/v eering; walk er or both hands of ex aminer needed. 
5 - Cannot walk ev en with assistan ce (wheelchair bo und). 
 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 48 of 49                                  CONFIDENTIAL  
                            TO TAL UPRIGHT  STABILITY SCORE 
 
 
                         TOTAL NEUROLOGIC  EXAMINATION SCORE 
IV.  INSTRUMENTAL TESTING 
 
 
2.   N ine-Hole P egboard  (Make su re the stopwatch is set to zero.  Introdu ce this section by say ing, "Now, we’re 
going to be meas uring yo ur arm and ha nd function ."  If this is the first vis it, as, "Are you right -  or  left-
hand ed?"      Make a note  of the dominant  hand for subsequent  instructions .  Place the 9-HPT a pparatus 
on the table direc tly in front of the patient .  Arrange th e apparatus so th at the side with the pegs is in front of 
the hand being te sted and the side with th e em pty pegboard is in fr ont of t he hand not being tested .  Sec ure with 
Dycem.  Read  the foll owing instructions to the patie nt:  "On this test, I want  you to pick up the pegs one at 
a time, using one han d  only, a nd  put  them  into the holes  as quickl y  as you can in a ny order until  all the 
holes  are filled.   Then , without  pausing , remove  the pegs one at a time an d return  them to the container  
as quickl y as you ca n.   We'll have you do this two (2) tim es with  each hand. We’ll start  with your  
[DOMIN ANT] hand.    You can  hold  the  peg board steady  with  you [NON-DOMIN ANT] hand.   If a peg 
falls onto the tabl e, you retriev e it and continu e  with  the task.   If a peg falls on t he floor, keep  working on 
the task a nd I will retrieve it for you.  See how fast you can p ut all the pegs in a nd take  them o ut again.  
Are your ready? Begin." 
 
Start timing as soon as the patient touches th e first peg, and stop timing wh en the last p eg hits th e container .  If a 
peg drops on the floo r, the ex aminer will retrieve i t and put it back in the p eg box. How ever, if a p eg drops onto 
the table,  the pa tient is to retrieve it unless it is bey ond their ar m reach  then you can retrieve it for th em.  It is 
possible that a p eg may fall bey ond the reach  of th e examiner therefore; we r ecom mend that you k eep a few 
extra pegs i n hand so th at testing is no t interrupted .  Do not put extra  pegs in th e testing apparatus as this may 
confuse th e subject.  Record the pa tient's time under " Dominant hand -- Trial 1. "  If the subject stops after 
having put all th e pegs into the holes, prompt the subject to move th em as well by saying, "And now remove 
them all."  If the subject be gins to remove mo re than one peg at a time, correct him/h er by saying, "Pi ck up one 
peg at a time."  
 
The to
tal time to complete th e task is recorded in sec onds including one d ecimal place  rounded as needed .   
Round up to the next tenth if hundredth's pl ace is > = . 05, round d own in hu ndredth's place  is < 0. 5.) 
 
RIGHT   LEFT  
 
Trial 1  Trial  1 
 
 
 
Trial 2  Trial 2 
  
 
AVG  AVG 
 
 
Attachment  II 
Protocol Schedule of Event 
IRB # 15 -006845; (+) Epi to treat FA   Version 5 
Revised  Jan 27 2017  
 
   
 
Mayo Clinic                                           Page 49 of 49                                  CONFIDENTIAL  
  
a (+)-EPI drug levels and follistatin/myostatin levels will be analyzed by UC -San Diego. All other laboratory analyses will be 
conducted by Mayo Clinic Department of Lab Medicine and Pathology and Research Laboratories 
a (+)-EPI drug levels and follistatin/myostatin levels will be analyzed by UC -San Diego. All other laboratory analyses will be 
conducted by Mayo Clinic Department of Lab Medicine and Pathology and Research Laboratories 
b: Serum BNP, Calcium, cardiac troponin  I, Complete Blood Count  (includes RBCs, WB Cs with differential , platelets) , 
ceruloplasmin, creatinine with eGFR, frataxin, glucose tolerance test  (not performed week 12) , hemoglobin A1C,  iron, 
mitochondrial complex I -V, potassium, PT/PTT, sodium, ST2, triglycerides , liver enzymes (AST, ALT, Alk phos) 
c: F2-isoprostane  
d: Magnetic resonance imaging  of cerebellum and spinal cord, m agnetic resonance spectroscopy  
e: Urine  pregnancy test (females  of childbearing potential)  
f: (+)- EPI orally administered daily  for 24 weeks  
g: (+)- EPI dose will be increased from 75mg/day to 150mg/day, if 8m timed walk via FARS assessment or cardiac evaluation 
shows no improvement or worsens  
h: Study site staff will contact the subject/LAR approximately every 15 days between the Baseline, Week 12 and Week 24 visits to 
assess clinical changes, adverse events and dosing compliance.  
i.  Respiratory chain function, aconitase, catalase, PGC1α, SOD2  in blood  if needed  
 15-006845    Protocol Schedule of Events  
Study Activity  Week 0  
Baseline  
Clinic Visit  Interim 
Contacts  Week 3  
(+/- 1 week)  
Lab Only  Week 12   
(+/- 1 week)  
Clinic Visit  Interim 
Contacts  Week 24  
(+/- 1 week)  
Clinic Visit  
Visit  1   2  3 
Review Eligibility  X      
Informed Consent  X      
Medical History  X   X  X 
Concurrent Medications  X   X  X 
Physical Exam /Vitals/BP  X   X  X 
Drug Level (+) - EPI a  X  X X  X 
Follistatin/Myostatin  a X  X   X 
Blood labs b X   X  X 
Urine Analysis  c X     X 
Neuro Studies  d X     X 
Cardiac MRI/BOLD  X   X  X 
Echo/ECG/Perfusion MRI  X     X 
FARS Assessment  X   X  X 
Urine Pregnancy Test  e X   X  X 
Dispense Study Med  
Dosing/AE Diary  f X   X   
Increase Dose, if appl  g    X   
Review D osing and AE 
diary     X  X 
(collect)  
Interim Contacts  h  X   X  
Off-study evaluation  i X     X 